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Abstract: 
Orthopaedic disease makes up a significant proportion of the caseload for the equine 
veterinary surgeon. Presentation of a patient with a septic synovial structure or osteomyelitis 
is one of the most serious disease processes in the spectrum of orthopaedic disease in the 
equine patient.  The complexities of achieving effective and successful therapy and 
minimising the long term complications are not only challenging but stressful for the 
attending clinicians.  
Traditional therapy of such conditions has involved surgical debridement of devitalised and 
infected tissue along with systemic antibiotic therapy. More recently improved outcomes 
have been achieved with the addition of local antimicrobial therapy to treatment regimes.  
Newer modes of antimicrobial delivery are currently sought after; ideally implants which 
will sustain local antimicrobial at therapeutic concentrations; are biodegradable; do not 
incite host inflammation; and do not inactivate antimicrobials during assembly.  This 
manuscript reviews orthopaedic infections in the horse, the modalities of therapy available 
the equine veterinarian, specifically newer modes of providing antimicrobial therapy, and 
efficacy of their use. Currently the ideal method of local antimicrobial delivery for 
orthopaedic infection in the horse has not been developed.  
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Pathogenesis of orthopaedic infection 
By definition osteomyelitis refers to an inflammatory process accompanied by bone 
destruction and caused by an infecting micro-organism.1 Infection and the resulting bone 
destruction can involve several regions of the bone – such as the cortex and the marrow 
(osteomyelitis) or cortex and periosteum only (more correctly termed osteitis). Osteomyelitis 
in the horse is relatively uncommon per se, however osteitis, involving the cortical bone, its 
periosteum and the surrounding soft tissue, is not an uncommon occurrence in the horse. In 
the adult orthopaedic infections include septic synovial structures, septic osteitis and 
osteomyelitis with the inciting cause being classified as haematogenous or post traumatic.  
Orthopaedic infection in the foal is almost exclusively joint associated occurring via 
haematogenous localisation of bacteria and has been classified into three categories based on 
the anatomic location of the infection.2 As amended from Firth 1983: 
• S type – presence of serofibrinous or fibrinopurulent arthritis with no macroscopic 
evidence of osteomyelitis at necropsy 
• E type – osteomyelitis of the epiphysis at the subchondral bone junction 
• P type – osteomyelitis directly adjacent to the physis 
A number of host factors that have been identified that may predispose the development of 
septicaemia and haematogenously localising infections. Inadequate transfer of colostral 
immunoglobulins,3 or the use of corticosteroids suppressing the immune response,4 
increasing the susceptibility for the development of pneumonia, diarrhoea, and umbilical 
infections. Bacteraemia can then follow seeding from these primary sites of infection. 2,4,5 
The anatomy of the vasculature within the neonatal metaphysis is thought to promote the 
transmural localisation of bacteria.6 In human infants minor trauma is thought to lead to 
 Page 8 
 
hematoma formation, vascular obstruction, and subsequent bone necrosis that is susceptible 
to inoculation from transient bacteraemia,7  which can occur due to minor trauma from 
routine tooth brushing - which leads to bacteraemia 25% of the time.8 In rabbit models of 
acute haematogenous osteomyelitis it has been shown that trauma increases the chance of 
infection in presence of concurrent bacteraemia.7,9 A similar disease process may occur in 
the horse however the exact pathogenesis remains unknown in the horse.  
Synovial sepsis results when the size of the inoculum (dependant on the individual micro-
organism virulence and pathogenicity) overcomes the inherent synovial defence 
mechanisms. 5,10  Colonisation of synovial spaces leads to a marked inflammatory response, 
initiated by the release of enzymes, free radicals and inflammatory mediators from 
synoviocytes.5,10 The inflammatory cascade leads to the production and release of a 
multitude of destructive enzymes and mediators, such as interleukin-1, tumour necrosis 
factor and free radicals, which all act to disrupt the normal synovial homeostasis, cell 
metabolism, and synovial membrane permeability.11 This culminates in a severe imbalance 
in cartilage homeostasis with activation and release of metallomatrix proteinases (zinc 
dependant endopeptidases) which play a key role in cartilage degradation, and joint 
pathology.12 
In the adult equid most cases of cases of synovial sepsis and osteomyelitis can be classed as 
post traumatic, secondary to external or surgical trauma and contamination of the wound. 
Aside from direct inoculation of contaminants into synovial cavities and bone, trauma 
contributes to the development of infection by damaging adjacent tissue, reducing blood 
supply to the affected area, which can lead to the formation of necrotic regions of inert 
tissue. Bacteria are then able to adhere to this tissue and infection then follows. 13 Trauma to 
the local tissues and wound formation has been shown to depress the local immune and 
inflammatory defences to bacterial infection, with an increasing degree of severity of tissue 
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injury having an increased risk of infection.14 Interestingly the presence of bacteria in a 
wound alone has been shown to be insufficient to cause osteomyelitis.14  
Osteomyelitis may result when overwhelming contamination is combined with severe 
trauma, dead bone or metallic implants; especially when bone fragments or implants are 
unstable.15 Surgical site infection is reported to occur in 10% of orthopaedic surgical cases in 
the horse - of which 50% have been classed as clean contaminated surgeries.16 This is a 
significantly larger proportion of post-operative infections compared to our counterparts in 
the human field of orthopaedics, where surgical site infection is reported to occur at 1.3% in 
total hip arthroplasties, otherwise at rates less than 1% for all other procedures.17 Various 
risk factors for the development of post-operative infection have been identified in humans 
and in the horse: 
• Patient related factors – obesity, prolonged hospitalisation, malnutrition, 
colonisation with methicillin resistant Staphylococcus aureus.17 
• Surgical factors: 
o Procedure (clean, clean contaminated, contaminated and dirty16,18), surgical 
preparation (scrub solutions, hair removal, draping and surgical field 
barriers), surgical facility (airflow, drapes, gowns, masks), surgical 
technique (atraumatic, aseptic, instrumentation), surgery duration, post-
operative care (incision care, peri surgical antimicrobial therapy).17 
o Duration of surgery – the longer the duration of surgery the greater the 
exposure of the tissue to environmental contaminants .19 
o Lack of debridement of contaminated or devitalised soft tissue and bone – 
avascular bone acts as nidus for chronic inflammation and infection. The 
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decision for removal of bone fragments should be based on fragment size, 
importance to stability, and amount of soft tissue attachments.19 
o Unstable implants .19 
• Environmental factors – method of recovery, cleanliness of recovery facility, 
dressing of the surgical site for recovery. 
The development of biofilms challenges to our ability to treat orthopaedic infections in the 
horse, as they promote attachment of bacteria through synergistic tropism; they are 
inpenetratable by inflammatory cells and antibiotics; they inhibit host inflammatory cells 
and phagocytosis; persistent host inflammation pleads to more tissue damage and allowing 
for ease of spread of bacteria, exposure of new surfaces for adherence and an abundance of 
nutrients that can be taken up by bacterial colonies for growth.1,20,21 The inherent resistance 
of biofilms to antimicrobial factors seems to be mediated by several factors including 
reduced metabolic rate, adaptive stress responses and down regulation of cell division of the 
deeply embedded microbes.1 Within biofilms bacteria can multiply and differentiate in 
multiple species. Antibiotics conventionally are selected for their efficacy against 
exponentially growing planktonic cells, not against biofilm cells, which largely explains 
there lack of effectiveness in treating biofilm related infections.22 
Chronically the hallmark of osteomyelitis is the presence of an involucrum – a region of 
live, encasing bone that surrounds infected dead bone within a compromised soft tissue 
envelope.23 This challenges the therapy of orthopaedic infection due to the dead bone acting 
as a nonliving surface for the attachment of bacteria and the formation of a biofilm.13 
It has been shown in animal models that some form of bone damage – mechanical, chemical 
or insertion of a foreign body is required to reliably establish infection.24 In humans the risk 
of subsequent infection is highly correlated to the degree of soft tissue injury associated with 
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the open fracture.25 Traumatised soft tissue and bone leads to exposure of potential binding 
sites for bacteria to attach. Tissue trauma compromises perfusion leading to tissue and bone 
necrosis – which can act like a foreign body in this setting, posing as a nidus for bacterial 
infection.24 Trauma has been reported to alter the host response to infection by suppressing 
the acute inflammatory response to the presence bacteria and depressing cell mediated 
immunity.24 Trauma impairs the function of polymorphonuclear leukocytes, including 
chemotaxis, superoxide production, and microbial killing. 26 
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Diagnostic modalities 
Osseous infection in the horse is characterised by lameness which can vary according to the 
severity and duration of the infection. Acutely heat, swelling, and pain on digital palpation 
of a wound or surgical incision may be noted.27 Sinus tract formation and exudate drainage 
from the site develop. Systemically the animal remains otherwise unchanged apart from a 
variable fever. In cases of septic osteitis the animal may present with a mild lameness and a 
non-healing wound.27 Osteomyelitis in the horse is nearly always associated with moderate 
to severe lameness as do cases with synovial sepsis.28 Open drainage of infected synovial 
structures, intra-synovial medication with corticosteroids, or administration of systemic anti-
inflammatories may lessen the degree of lameness at the time of examination.5 On physical 
examination vital parameters are usually within normal limits, with variable fever present.28 
Synovial effusion, heat, swelling and palpation of the structure and surround soft tissues are 
key findings for localisation of the infected structure. Alternatively a wound adjacent a 
synovial structure may identified.28  
Synovial contamination and sepsis associated with wounds can be confirmed by observing 
communication of the synovial structure and the wound. Gross examination of synovial fluid 
at the time of collection, assessing the colour and turbidity can give some very useful 
information. Sepsis usually results in turbid, flocculent and non-viscous synovial fluid due to 
increased cellularity and total solid content of the fluid.29 Synovial fluid cytology is the gold 
standard for confirmation of synovial sepsis.28 Normal synovial cytology yields a 
predominantly mononuclear cell population, <10% neutrophils with a total white blood cell 
count <5x109 cells/L, and total protein <20mg/L. Findings of  >80% neutrophils with 
variable toxicity, a total white blood cell count > 10x109 cells/L and a total protein > 40mg/L 
are consistent with synovial sepsis.29 Only 25% of cases will have bacteria identified on 
cytology. 5,30  
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In most cases of equine orthopaedic infection peripheral blood samples most consistently 
display a hyperfibrinogenaemia with or without a leucocytosis (marked leucocytosis 
characterised by a neutrophilia is an expected finding in the foal).30-32 Blood samples should 
be submitted for aerobic and anaerobic culture and sensitivity if the animal has evidence of 
systemic disease.28 
In cases of osteomyelitis deep aspiration of fluid accumulations should be examined 
cytologically to determine their nature and the presence of infectious agents along with 
submission of a sample for culture and sensitivity testing.27 Cytology consistent with 
infection usually contains a predominance of neutrophils and a low number will also contain 
the offending pathogen also.  Samples for culture should be inoculated directly in to 
commercial broth to enhance pathogen growth and reduce sample turn-around time.27  
Many imaging techniques are available for diagnosing equine orthopaedic infections 
including radiography, magnetic resonance imaging (MRI), computed tomography (CT), 
Scintigraphy and more recently biomarker analysis. The accuracy of diagnostic imaging 
modalities for detecting orthopaedic infection in humans is approximately 80-90%.33 
Radiography remains the most commonly used modality for diagnosis of osseous 
involvement in synovial sepsis and osteomyelitis in equine practice; however it is a very 
insensitive method for diagnosis due to the requirement of 50-70% demineralisation of the 
affected bone before being radiographically identifiable as lysis on plain films. This can lead 
to a significant lag period between onset of infection and identifiable changes present on 
radiographs of up to 21 days.5,27 Contrast radiography can be implemented to determine 
communication of a draining sinus or wound with neighbouring joints and bone, along with 
identification of cartilage defects not observed on plain radiographs.28  
Ultrasonography in conjunction with other imaging modalities, such as radiology, also 
provides invaluable information – the extent of subtle periosteal irregularity, the presence of 
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radiolucent foreign bodies with in wounds, and contributes to accurate collection of samples 
for diagnostic purposes.28 Ultrasound can allow examination of anatomic regions not easily 
assessed by physical or radiographic examination, such as the shoulder joint.5 
Ultrasonography however can lead to patient discomfort, only allows assessment of 
periosteal surface, and hence cannot identify sclerosis or lysis of bones. 
Computed tomography is being used more frequently in the diagnosis of orthopaedic 
infections in the horse, especially in anatomic regions which have been previously hard to 
interpret with radiographic studies. Computed tomography not only provides clear anatomic 
detail of osseous structures, but reveals changes earlier in the disease process compared to 
conventional radiography.34 Computed tomography is capable of identifying, and is superior 
to magnetic resonance imaging, in detection of sequestra, cloaca’s, involucra and 
intraosseous gas.35 Contrast enhanced computed tomography enables distinction between 
necrotic tissues from surrounding normal tissue.27 The presence of metal in close proximity 
to osteomyelitis leads to a significant reduction in image resolution due to beam hardening 
artefact thereby complicating interpretation of changes at the bone-implant interface. 36 CT 
in horse is not widely available at this point in time; carries a significantly greater cost than 
more traditional forms of imaging; and also carries the inherent risks of general anaesthesia 
to undertake the study. 
Magnetic resonance imaging allows for early detection of osteomyelitis and an accurate 
assessment of the extent of the disease with excellent structural definition and spatial 
resolution.35 Magnetic resonance imaging has been found to have the highest sensitivity in 
detection of lysis in the order of 3-5 days following the onset of infection.37 The combination 
of STIR and T1 spinecho sequences shows a high specificity and sensitivity for detection of 
osteomyelitis.38 Contrast enhanced magnetic resonance imaging with gadolinium allows for 
more accurate detection of sequestra and involucre.35 Due to the magnetic fields involved in 
developing an image, metal implants cannot be used with this imaging modality.35 The 
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development of standing units for imaging the distal limbs of the horse avoids the risks 
associated with general anaesthesia in the horse, however low availability and high cost have 
limited the common day use of this modality in diagnosis of equine orthopaedic infections. 
Nuclear medicine is being utilised more frequently in combination with other methods of 
imaging to for localisation and diagnosis of orthopaedic infections. The extremely high 
sensitivity of this modality of imaging is coupled with a very low specificity for the 
diagnosis of osteomyelitis hence requires of other imaging modalities to differentiate 
osteomyelitis from fractures, arthropathies, neoplasia, or cellulitis.39   
Serum biochemical markers have been investigated as a non-invasive means of specifically 
detecting changes in bone metabolism that may indicate post-operative osteomyelitis. 
Specifically osteocalcin, bone specific alkaline phosphatase and deoxypyridinoline have 
been examined in the rabbit and were found to have an accuracy of 96% for predicting 
osteomyelitis at 4 weeks in a rabbit femoral fracture model.40 In this model the biochemical 
markers predicted osteomyelitis before any changes could be observed on conventional 
radiographs. The biochemical changes observed with osteomyelitis in the rabbit model has 
not been validated in horses; and remains a research application only. 
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Common pathogens implicated in Equine orthopaedic infections: 
The spectrum of pathogens implicated in orthopaedic infections can vary with animal 
signalment; type of osteomyelitis; location of the disease; geographical location; and the 
presence of an open wound or implant. In cases of haematogenous osteomyelitis in foals 
gram negative enteric bacteria are predominately isolated with Escherichia coli reported as 
the most frequent isolate.2,41 More recently an increased prevalence of isolation of 
Streptococcus, Staphylococcus and Salmonella spp in blood cultures from foals with septic 
arthritis/osteomyelitis has been reported, with Escherichia coli more commonly isolated 
from infected bone samples.42 The pathogen isolation in equine neonates is in contrast to that 
of human neonates and infants with septic arthritis and osteomyelitis. In the human field, up 
until the 1940’s gram positive isolates were the cause for bacteraemia’s however the 
prevalence reduced markedly with the introduction of antibiotics. More recently gram 
positive isolates have accounted for bacteraemia in humans with Staphylococcus aureus 
isolated most frequently in cases of haematogenous osteomyelitis with a prevalence of 60 -
90%, followed by Streptococcus species at a prevalence of 20-50%.43 The re-emergence of 
gram positive isolates has been attributed to antimicrobial regimes that promote resistance 
and the increased rate of invasive procedures providing the opportunity for nosocomial 
infection. 44,45 There have reports of relative increases in the incidence of gram positive 
isolates in blood cultures from bacteraemia foals; however this appears to be confined to 
certain hospitals and may reflect increased incidence in neonatal nosocomial infection.46 
Isolates from adult horses with osteomyelitis or septic arthritis in association with a wound 
contained mixed infections with Enterobacteriaceae, non-beta haemolytic Streptococci, 
coagulase positive Staphylococci, beta-haemolytic Streptococci, and coagulase negative 
staphylococci in order of decreasing frequency respectively.47 The antibiotic resistance 
patterns of equine orthopaedic isolates from 1974-1979 were compared to those from 1980-
1985 and revealed that there was an increase in percentage of coagulase positive 
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Staphylococci to all antibiotics except oxacillin and amikacin, along with Escherichia coli 
isolates resistant to all antibiotics except amikacin.48 Mixed isolates are also commonly 
encountered with osteomyelitis associated with an implant or fracture repair, with 
Enterobacter spp and coagulase positive Staphylococcus species the most commonly 
isolated gram negative and positive pathogens respectively.49 In contrast, iatrogenic 
infections of joints following joint medication or surgery commonly isolate a pure growth of 
Staphylococcus species. 47  
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Table 1. Summary of sensitivity patterns and isolates amended from Moore et al Sneider et al; Synder; Goodrich 
Population Problem Most common 
organism isolated 
Antibiotic most 
likely to be effective 
References 
Foals Haematogenous 
osteomyelitis/physitis 
Enterobacteriaceae Amikacin, 
Cephotaxime 
Moxalactam 
Wilson and 
Madigan 1989; 
Schneider 1992 
Mature Iatrogenic septic 
arthritis 
Staphylococci Amikacin Schneider 1992 
Mature Septic arthritis 20 
wound 
Mixed: 
Enterobacteriaceae 
β Streptococcus 
Staphylococcus 
haemolyticus 
Nonhaemolyticus 
 
Amikacin 
Cephalothin 
Amikacin 
Amikacin 
Schneider et al 
1992 
Mature Osteomyelitis 20 
wound 
Enterobacteriaceae Amikacin Synder 1987 
Mature Osteomyelitis 20 
implant /# repair 
Mixed: 
Enterobacteriaceae 
Non β Streptococcus 
coagulase positive 
Staphylococcus 
β streptococcus 
 
Amikacin 
Chloramphenicol 
TMS 
Amikacin 
Cephalothin 
Snyder et al 1987 
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Treatment: 
Surgical curettage: 
A combined antimicrobial and surgical approach should be considered in all cases of 
osteomyelitis.1 Debridement of the lesion is essential for the removal of avascular bone, 
purulent material, necrotic debris.15 Avascular bone acts as a continual source of 
inflammation; leading to isolation from vascularisation by development of an enveloping 
layer of granulation tissue there by preventing resorption of the bone (sequestra formation) 
and impeding bone healing.15 This not only suppresses healing but also reduces deposition of 
systemically administered antimicrobials.50 In cases of haematogenous osteomyelitis in 
human neonates, and infants, surgical therapy is generally unnecessary, with intense medical 
therapy adequate for a successful outcome; which is in stark contrast to post traumatic 
osteomyelitis of fracture repair in which surgical removal of the infected fragments and 
foreign bodies can lead to a successful outcome with little antimicrobial therapy.1 
A number of surgical techniques have been described for management of septic synovial 
structures with all aiming to physically remove bacteria, devitalised tissue, inflammatory 
products and wound debris.28 Synovial aspiration, 4,51 distension-irrigation,4,51 through-and-
through lavage,4,10,51 arthrotomy,5,10,30 drains,5,10 and endoscopy,5,10,52 have all been described 
for use in the horse.  Endoscopic lavage and debridement of septic synovial structures carries 
a number of advantages when compared to other methods of management. These include 
improved visualisation, allowing accurate evaluation of the structure; identification and 
debridement of foreign material, devitalised and necrotic tissue; improved access to a greater 
proportion of the synovial cavity; minimal morbidity; reduced hospitalisation; maximal 
function recovery; and more accurate prognosis for recovery.10,53-55 The implementation of 
endoscopic lavage and debridement for septic synovial structures has led to improved 
success of therapy of synovial sepsis in the horse.5,10,52   
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Antibiotic therapy: 
The introduction of antimicrobial drugs in the 1940’s revolutionised human and veterinary 
medicine by allowing economic and effective treatment of bacterial disease. The widespread 
use of antimicrobials in human and veterinary medicine since there discovery has coincided 
with the simultaneous development of bacterial resistance. The therapeutic benefits (clinical 
improvement) from the use of antimicrobials occurs due to facilitating the host immune 
systems removal of microbes via  direct bacterial cell death or inhibition of bacterial cell 
growth.56 Antimicrobials have been classified into two main categories; those that are 
concentration dependant where increasing concentrations at the focus of infection improve 
bacterial kill; or time dependant where exceeding the MIC for a prolonged percentage of the 
inter dosing interval rather than maximal concentration above MIC correlates with improved 
efficiency of bacterial kill.57  Adverse effects from administration of antimicrobials can 
occur as a result of primary pathology to specific organs or generalised systemic 
reactions,58,59 alternatively, adverse reactions can occur secondarily due to the antimicrobials 
affecting commensal bacterial populations, promoting overgrowth by pathogenic 
organisms.60 The study of the pharmacokinetic and pharmacodynamic properties of 
antimicrobial agents, and their interactions, has led to proposed outcomes in regards to 
clinical improvement, growth promotion and adverse reactions.57  
To reduce the incidence of antimicrobial resistance in bacterial populations, and prevent its 
ongoing development, it is of extreme importance that the most effective antimicrobials are 
selected for use, administered by the most optimal route, and at the most effective dose. To 
reduce the selection pressure on commensal bacterial populations it is implicit that the 
optimal dosage strategy to remove the offending pathogen delivers the minimal appropriate 
dosage to remove the target species.57  Further pharmacokinetic and pharmacodynamic 
parameters can be determined which minimise the selection window for resistance 
associated with the target pathogen.61 
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Pharmacokinetics and pharmacodynamics: 
Pharmacokinetics is the study of the movement of drugs in the body including the processes 
of absorption, distribution, localisation in tissues, biotransformation and excretion.62 The 
pharmacokinetic data provides a guide as to the concentrations achievable within tissues –
from the maximum plasma concentration (Cmax) and area under the plasma concentration – 
time curve (AUC).  
Pharmacodynamics is the study of the mechanism of action of drugs and other biochemical 
and physiological effects.62 Pharmacodynamics provides a guide as to the in vitro interaction 
of the antimicrobial agent and the micro-organism.  
The most important parameters of pharmacokinetics are the area under the plasma 
concentration time curve from 0 to 24 hours (AUC0-24), the maximum plasma concentration 
(Cmax)  and the time (T) during which concentrations exceed a defined pharmacodynamic 
threshold.57 The most useful pharmacodynamic parameter is the minimum inhibitory 
concentration (MIC) the lowest concentration of antimicrobial which inhibits the growth of 
the target bacteria.63  Efficacy however may depend upon achieving concentrations in 
plasma several fold higher than the MIC of the pathogen,64 alternatively it may be dependent 
on maintaining concentrations in plasma just above MIC for a prolonged period of time.65 
For concentration dependant antimicrobials (aminoglycosides and fluoroquinolones) the 
pharmacodynamic indices that predict the efficacy of the antimicrobial against an organism 
are the Cmax:AUC and the AUC:MIC – maximum efficacy has been reported to occur when 
the Cmax:MIC>10 and the AUC:MIC>125.
66 For some pathogens and drugs it is more 
complex and requires a combination of concentration and time of exposure (Co-
dependency), as is the case with glycopeptide antimicrobials such as vancomycin.67 In the 
study of pharmacokinetics the site of measurement of the concentration may be an issue as 
plasma concentrations may not reflect the concentration of the drug at the site of the 
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pathogen (i.e. CSF, intracellular or intraocular). It must also be taken into consideration that 
the MIC is determined in culture broth and not in the environment in which the bacteria is 
growing in vivo – i.e. blood, synovial fluid, pus, intracellular fluid.  The pH, aerobic or 
anaerobic environment, and growth phase, are also important in vivo; particularly in specific 
anatomical or physiological locations such as the mammary gland or urine, or in 
pathological situations of severe inflammation or abscessation.57  
The in vitro activity of some drugs does not accurately reflect there in vivo activity due to 
the post antibiotic effect (PAE) and post antibiotic leukocyte enhancement PALE.56 PAE is 
the persistent suppression of bacterial growth following removal of an antimicrobial from 
the locus of the bacteria,68 and is specifically defined as the time required for an organism to 
demonstrate viable regrowth following removal of an antibiotic.69 The occurrence and 
magnitude of the PAE is dependent on the micro-organism and the type and concentration of 
the antimicrobial along with the duration of exposure.57 The mechanism for PAE vary: for 
beta lactams - the length of time it takes for the bacteria to synthesis new penicillin binding 
proteins; for aminoglycosides, the length of time taken for the drug to disassociate from the 
ribosome and diffuse from its site of action, and then for protein synthesis to recommence.57 
Beta lactams express PAE for gram positive bacteria only. Antimicrobials that inhibit DNA 
or protein synthesis tend to impart long PAE for gram negative bacteria.56 The PALE 
describes the increased susceptibility to phagocytosis and intracellular killing demonstrated 
by bacteria following exposure to an antimicrobial drug. In vivo, the PAE effect for 
aminoglycoside’s is prolonged by the synergistic effect of host leukocyte activity – it is 
believed that leukocytes have enhanced phagocytosis and killing activity after exposure to 
aminoglycoside’s - post antibiotic leukocyte enhancement.70 
Repeated exposure to sub-optimal drug concentrations is now recognised as the single most 
important factor for the emergence of resistance.71 Optimal dosing strategies may acquire the 
appropriate drug concentrations for the appropriate amount of time for target pathogens 
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however commensal organisms may express differing sensitivities and therefore be selected 
upon for resistance, which could transfer resistance genes to pathogen bacterial 
populations.72  
Therapy for equine orthopaedic infections has revolved around the use of beta lactam and 
aminoglycoside antimicrobials, whilst waiting for specific culture and sensitivity results. 
Beta lactams are classed as time dependant antimicrobials where by the time that the drug 
remains above MIC is the greatest determinant of likely efficacy.73 Exceeding the MIC by 1-
5 times for 40-100% time of the inter-dosing interval is thought to be highly specific.74 In 
deep-seated infections penetration of the beta lactam to the site of the bacterial locus may 
depend on the plasma concentration as the process of distribution will depend on local blood 
flow and simple diffusion down the concentration gradient of the drug. The AUC0-24  and 
Cmax  thereby play an integral role in the distribution and activity of time dependant 
antimicrobials.75 Controversy remains as to the effect of the magnitude by which the 
concentration of time dependant antibiotics, such as cephalosporins, exceeds MIC and its 
influence on activity.76 Some data supports the theory that the Cmax  achieved with beta 
lactam antimicrobials influences that kill.77 
Aminoglycosides are classed as concentration dependant antimicrobials for the gram 
negative bacteria for which they are commonly used against;78 however they do impart some 
concentration independent activity when used as an adjunct therapy for gram positive 
bacteria. The Cmax:MIC ratio has been shown to be the most useful pharmacokinetic and 
pharmacodynamic indicator of predicting the efficacy of aminoglycosides, with increasing 
Cmax:MIC correlating with clinical response. A Cmax:MIC>10 has been recommended for 
once daily therapy however care needs to be taken to avoid toxicity. Toxicity of 
aminoglycosides is related to the trough period below the threshold that would incite 
toxicity.79 
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Traditional therapy for osteomyelitis has consisted of systemic antimicrobial therapy and 
improvement of the wound environment.15 Systemic antimicrobials were the corner stone of 
therapy however there use alone inevitably has been inadequate in many cases for the 
treatment of severe osteomyelitis or synovial sepsis.27  Administration of intravenous 
gentamicin at 6.6mg/kg once daily has been reported to reach a Cmax within 1.4 hours at 
approximately 5 times the MIC of most pathogens encountered in equine orthopaedic 
infections.80 The reported half-life of gentamicin in equine tissue is 1.4 hours,81 thereby the 
concentration of gentamicin would be below the reported MIC for most pathogens within 6 
hours, however with an estimate of the duration of the post antibiotic effect the expected 
duration of effective concentrations of gentamicin would be approximately 13 hours which 
may be an ineffective regime for severe orthopaedic infections in the horse.80 The 
combination of gentamicin with a beta lactam antimicrobial may prolong the effective 
concentration of gentamicin due to the recognised synergism between the two 
antimicrobials.81  
Parenteral administration of gentamicin has been shown to reach significantly lower Cmax in 
synovial fluid, synovial membrane, joint capsule, and subchondral bone of healthy horses 
compared to that achieved with local antimicrobial administration.80 High concentrations of 
systemic antimicrobial are required to attain sufficient local levels in contaminated tissues 
with compromised vasculature which not only increases the risk of systemic toxicity and 
side effects but also promotes the evolution of bacterial resistance.82 Systemic antibiotic 
therapy also has the drawback of the significant cost associated with medicating the average 
weight horse. However in spite of this systemic antimicrobial therapy still plays a role in the 
management of osteomyelitis in the horse in combination with local delivery techniques.27 
The first line of systemic broad spectrum antibiotic therapy or prophylaxis in equine practice 
usually comprises a combination of penicillin and gentamicin which has been shown to 
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provide consistent broad spectrum of coverage, is relatively cheap and has minimal side 
effects.50  
The use of local antibiotic delivery techniques arose in Europe in the 1970’s with the advent 
of joint arthroplasty techniques in humans. Early reports found that penicillin, erythromycin 
and gentamicin mixed into the cement used to fix prosthesis to bone lead to high local 
concentrations of the antimicrobials that persisted for an extended period of time.83 The 
institution of local antimicrobial delivery methods into the prophylaxis for, and treatment of, 
a number of human orthopaedic conditions has led to significantly improved success rates. 
The use of local antibiotic delivery methods in the veterinary field has also developed, albeit 
at a slower rate, however having the same positive impact on successful therapy. 
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Local Antimicrobial delivery 
Local antibiotic therapy has led to concentrations of antimicrobials at the bacterial locus that 
are many times the MIC of the offending organisms for a significantly longer period of time, 
low systemic concentrations thereby avoiding systemic toxicity and a significant reduction 
in costs associated with therapy, all of which have resulted in a significant improvement in 
the successful treatment of horses with orthopaedic infections.27 The modes of local 
antibiotic delivery that are currently available include: 
• Antimicrobial impregnated polymethylmethacrylate 
• Intravenous and intra-osseous regional limb perfusion 
• Intra-articular/intrathecal medication 
• Biodegradable implants: 
o  Calcium sulphate based implants 
o Calcium phosphate based implants 
o Chitosan based implants 
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Antibiotic Impregnated Polymethylmethacrylate: 
The use of antimicrobial impregnated polymethylmethacrylate (AIPMMA) implants for the 
prevention and treatment of osteomyelitis in horses has drastically improved the success rate 
of therapy over the past 30 years.27 The concept of using AIPMMA is based on the principle 
that antibiotic will be slowly released from the cement over time, thereby achieving 
continuous antimicrobial action in situ.84 Implantation of AIPMMA results in high local 
antimicrobial concentrations for a prolonged period of time. The slow local release of 
antimicrobials can result in concentrations within the wound fluid of up to 200 times that 
which could be achieved with systemic administration of the same drug and maintain 
antimicrobial concentrations above MIC can last for up to 80 days after implantation.85-87 
Variable reports of the efficacy of this local form of therapy for treating osteomyelitis in the 
horse have been described, with success rates in the vicinity of 80% reported. In the human 
field prophylactic use of AIPMMA has resulted in a 34% reduction in orthopaedic surgical 
infection rates.88,89   
 Antimicrobials diffuse through the cement down the concentration gradient in to the 
surrounding local tissue in a bimodal elution pattern– with rapid elution over the first 24 
hours with subsequent low levels of elution over the following weeks to months.88-90 Most 
researchers agree that the majority of antimicrobials are released from the cement in the first 
few hours to days, followed by a longer duration of elution at a substantially lower 
level.84,91,92 
Factors such as molecular weight of the drug, molecular weight and cross linking of the 
polymer, porosity of the cement, drug solubility in the polymer, surface area of the implant, 
concentration of antimicrobial in the implant and volume of fluid surrounding the implant all 
contribute to the elution characteristics of the antimicrobial from the implant.84 
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The elution rate of an antimicrobial from AIPMMA implants is directly proportional to the 
surface area of the implant –hence small rough spheres are recommended as these will have 
the greatest surface area to volume ratio27. The amount of antimicrobial impregnated within 
the PMMA is directly proportional to the amount that can be eluted and the maximal 
concentration of the antimicrobial in the eluent.27 Early reports found a variation in elution 
between the use of liquid and powdered antimicrobials in the construction of AIPPMA,93 
more recent reports have failed to attain the same result rather finding that the elution 
characteristics were unchanged between the use of powdered and liquid formulations of 
gentamicin and amikacin.94 
Due to the broad spectrum of activity of gentamicin in the human field, along with its 
bactericidal, heat stable and water soluble characteristics, much literature has focused on its 
use in AIPMMA.50 However in equine clinical practice amikacin has gained more wide 
spread use due to the broader spectrum of activity and efficacy of treatment against 
pathogens commonly encountered in equine orthopaedics.47,50 A range of antibiotics have 
been identified to have good elution characteristics from PMMA and include the following: 
amikacin, gentamicin, tobramycin, amoxicillin, ciprofloxacin, imipenem, ticacillin, 
cephazolin, clindamycin, vancomycin, erythromycin, metronidazole, fluoroquinolones.50 
The mechanical properties of the PMMA are altered with the addition of antimicrobial; 
measurable reductions in compressive strength occur even at very low concentrations.95 
Current recommendations in the production of AIPPMA beads is to impregnate less than 
10% antibiotic of the weight of the PMMA used to make the implants thereby minimising 
any reductions in the compressive and tensile strength of the implant when used for plate 
luting procedures.88 The ultimate compressive strength has also been shown to be effected to 
varying degrees depending on the antimicrobial impregnated; cephazolin has been shown to 
reduce the ultimate compressive strength less than that which occurs with gentamicin.84 Gas 
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sterilisation of the impregnated implants was shown to have a greater reduction in ultimate 
compressive strength compared to those which were stream sterilised.84  
More recent studies have highlighted that implants not used for fixation rather for local 
deposition of antimicrobials should contain antibiotics at the concentration which would 
achieve the normal systemic dose of the antibiotic and no greater, thereby avoiding potential 
systemic toxicity and preventing the potential antimicrobial resistance that could develop 
when antimicrobial concentration for impregnation to PMMA is based solely on the 
biomechanical properties of the implant.96  
The combination of different groups of antimicrobials for systemic administration is 
common practice to take advantage of any potential synergy of activity between different 
antimicrobial groups and to broaden the spectrum of activity of the antimicrobials. The 
clinical use of a combination of antimicrobials in PMMA for local antibiotic therapy is also 
used clinically however the combination of antimicrobials within the same implant changes 
the elution characteristics of the antimicrobials: significantly higher initial elution of 
antimicrobials occurs due to passive opportunism – increased elution of both antimicrobials 
due to increased porosity of the cement.97 Numerous combinations of antimicrobials have 
been studied and include the following: vancomycin/amikacin, cephazolin/amikacin, 
cephazolin/metronidazole, metronidazole/gentamicin.96,98 When comparing the co-elution of 
two antimicrobials from PMMA to those containing one antimicrobial only, the total 
antimicrobial eluted is significantly greater for co-elution, however the concentration of the 
antimicrobials in the eluent remain above MIC for common pathogens for a significantly 
shorter period of time compared to PMMA with one antimicrobial impregnated.96 The 
increased elution may result from increased porosity of the bead – with more antimicrobial 
added to the PMMA the surface pores enlarge, the bead surface roughens and more channels 
from the surface to the interior of the bead are formed.88 These changes serve to increase the 
surface area of the bead resulting in increased contact with the eluent fluid across the bead 
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surface and increased elution of the antimicrobial. There is also the potential that combining 
antimicrobials may result in a chemical reaction that leads to increased elution rates of 
antimicrobials from the PMMA.96 These changes in elution may not correlate with increased 
effectiveness – a greater rate of elution allows for more rapid depletion of antimicrobial 
stored within the PMMA and subsequent concentrations of the antimicrobial may fall below 
the appropriate MIC for the offending pathogen. This may be beneficial in prophylaxis of 
infection with implants however may not be beneficial in the treatment of pre-existing 
osteomyelitis, preventing resistance, or reducing systemic toxicity.96 Tobramycin/oxacillin 
combination has been identified as a combination that has a negative effect on elution.50 
Despite the significant improvement in success of therapy for osteomyelitis in humans and 
animals over recent decades with the use of antimicrobial impregnated 
polymethylmethacrylate, much research is directed toward developing biodegradable 
vehicles for local antimicrobial delivery. As PMMA is not a biodegradable substance, its use 
as an antibiotic impregnated bead clinically in humans necessitates a second surgical 
procedure for removal. In the veterinary field removal is not always required. The 
pharmacokinetic profile of antimicrobial elution form PMMA is not ideal – with initial peak 
concentrations followed by a significant reduction in concentration that may not maintain 
therapeutic concentrations.99 The trailing low concentrations of antimicrobial following the 
initial peak has raised concerns for potential propagation of antimicrobial resistance.100 The 
exothermic reaction (cement curing heat production) of the of PMMA has also raised 
concerns in potentially reducing the concentration of active antimicrobial impregnated 
within the bead (polymyxcin B, tetracycline, chloramphenicol 50), along with local tissue 
necrosis from thermal, mechanical and chemically induced effects.101 Further to this PMMA 
has been shown to have detrimental effects on the innate antibacterial properties of human 
serum in the normal patient - namely the cascade of proteins that make up what is commonly 
referred to as complement. It has been postulated that in the diseased patient where the 
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immune competency has already been compromised, the effect of PMMA could potentially 
compound the reduction in immune competence and promote infection.101 The most 
common clinical complication with the use of AIPMMA beads has been soft tissue damage 
on removal and the formation of fibrous connective tissue complicating removal.90 PMMA 
beads are not recommended for use in joints due to the abrasive damage that is incited on 
articular cartilage.102 There have also been limited reports of toxicity associated with its use, 
that being acute renal failure of a patient following use of gentamicin impregnated 
PMMA.103  
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Regional limb perfusion: 
Over the past decade regional limb perfusion has become a common method of for 
administration of local antimicrobials in the treatment of orthopaedic infection of the equine 
distal limb. Regional limb perfusion allows clinicians to achieve high concentrations of 
antimicrobial in the region of infection, which is thought to improve the success of therapy 
of treating bacterial infections.104,105 The technique involves exsanguination and isolation of 
the distal limb from the systemic circulation by application of an Eschmarchs tourniquet and 
then injecting the antimicrobial into the isolated vasculature.106 Infusion of the perfusate 
leads to distension of the vasculature in the isolated region of the limb, thereby creating high 
pressure and concentration gradients between the intravascular and extravascular 
compartments.107 It is imperative that proper application of the tourniquet is undertaken as 
isolation of the regional vasculature is essential for this technique to be effective.108 The 
infusion of perfusate leads to dilation of the venous capillaries, post capillaries and 
lymphatics, with relaxation of the contacts between the endothelial cells and pericytes, 
thereby creating spaces in the vascular wall for further diffusion without cellular damage.109 
This maximises the diffusion of antimicrobials in the perfusate from intravascular 
compartment in to the surrounding tissue, achieving high concentrations in poorly 
vascularised area’s of tissue that harbour bacteria which would otherwise remain potentially 
unaffected by systemically administered antimicrobials.106 Following removal of the 
tourniquet the perfused tissues serve as a depot for continued diffusion of the agent locally; 
maintaining high concentrations of the antimicrobial in the region for a significant period.106 
The perfusate is either administered via a superficial vein (intravenous regional limb 
perfusion) or injected directly into the medullary cavity of a bone (intra-osseous regional 
limb perfusion).106,110 The intra-arterial route has been discouraged due to the potential for 
more frequent and severe toxic effects on the arterial endothelial cells compared to that on 
venous endothelial cells.107 Reports of perfusion of the distal limb with radio-opaque dye 
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and Indian ink have revealed that the perfusate is distributed via the venous system with 
either form of administration.111 There is the potential for perfusate to migrate through the 
diaphysis and exit to the systemic circulation if via diaphyseal and epiphyseal vessels 
proximal to the tourniquet.105 Comparison of perfusate distribution with intravenous and 
intra-osseous administration of 99m-technetium pertechnetate revealed no difference in the 
radio nucleotide uptake in the distal limb of horses.108 However in a study comparing 
intravenous and intra-osseous administration of amikacin sulphate to the tarsal region in 
horses has revealed that the amikacin concentration in the tarso-crural joint was consistently 
higher following intravenous administration.111 The concentration of antimicrobial agents 
achieved within synovial fluid when performing regional limb perfusion is not as high as 
those achieved by direct intra-articular administration,112 however the concentrations within 
the joint and the surrounding soft tissue and osseous structures have been reported to achieve 
100 times MIC for periods up to 36 hours, which is advantageous when there is infected soft 
tissues along with synovial sepsis.105,111,113,114 Systemic administration of antimicrobials has 
been shown to be far inferior to regional limb perfusion with Cmax: MIC ratios achieved in 
the target tissues with the latter form of administration reported to be 3-30 times that 
achieved with systemic administration.105,111,113 
The dosing frequency of antimicrobials administered via regional limb perfusion is based on 
the pharmacokinetics/pharmacodynamics of the individual antimicrobial agents. 
Aminoglycosides are classed as concentration dependant agents as discussed previously, the 
greater the Cmax:MIC the greater antimicrobial effect they have, therefore once daily therapy 
or every second day therapy as a regional limb perfusion can be undertaken with 
aminoglycosides due to the long post antibiotic effect they exert. As cephalosporins are time 
dependant agents the proportion of time the concentration of the antimicrobial is above MIC 
rather then the Cmax determines the activity of the agent, therefore more frequent 
administration is required. Ceftiofur, a third generation cephalosporin, time dependant 
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antimicrobial, has been shown to remain above MIC most common pathogens of septic 
arthritis for greater than 24 hours in the radiocarpal joint following intravenous regional limb 
perfusion, indicating once daily administration should be adequate.115 Regional limb 
perfusion with time dependant antimicrobials has been shown to result in therapeutic 
concentrations in infected ischemic tissue for longer periods than with systemic therapy.107 
Optimal dosages used for regional perfusion in horses have not yet been determined,107 
however empirical dosages based on the limited number of studies on the pharmacokinetics 
of regional limb perfusion in the horse exist. 
The use of a single antimicrobial agent in the perfusate is the current recommendation107, 
despite a report of the successful use of a combination of antimicrobials.116 At the end of this 
chapter a table has been modified from Rubio-Martínez and Cruz, 2006107: “Antimicrobial 
regional limb perfusion in horses” (Table 2) which summarises  commonly used 
antimicrobials used for regional limb perfusion horses. 
The optimal volume of perfusate for regional antimicrobial perfusion has not been 
determined; the larger the volume of perfusate the greater the intravascular pressure 
achieved and therefore increased diffusion from the vessel into the surrounding tissue. 
However as intravascular pressure increases, so too does the risk of perfusate leaking under 
the tourniquet into the systemic circulation thereby reducing the effectiveness of the 
treatment.107 The anatomic location and horse size have influenced the volume of the 
perfusate used up to this point with wide variation in volumes reported. A volume of 
perfusate based on body weight has been suggested – 0.1ml/kg, which may provide a 
volume of perfusate proportional to the vascular volume of the individuals distal limb.117  
The tourniquet plays a very important role in ensuring the effectiveness of this form of local 
antimicrobial therapy. A measure of a tourniquets effectiveness is the maximum venous 
pressure that can be achieved during administration of the perfusate before perfusate leaks 
 Page 35 
 
under the tourniquet.118 Tourniquet pressure and width, patient characteristics, site and rate 
of injection, volume of perfusate, and previous exsanguination all influence the effectiveness 
of the tourniquet.118 It has been recommended that tourniquets should have a width 20% 
greater than the diameter of the limb, the limb should be exsanguinated prior to perfusion, 
and infusion rate should be low at a site distal to the tourniquet to increase the effectiveness 
of the tourniquet.118 
Pneumatic tourniquets are preferred over rubber tourniquets as the pressure applied to the 
limb is evenly distributed, can be measured and monitored.119 Tourniquet complications are 
reduced when applied over well-muscled regions of the limb where the nerves and vessels 
are protected with soft tissue, and when the tourniquet pressures are the minimum required 
to prevent leakage.119 The tourniquet pressure required to stop bleeding when used for 
haemostasis has been reported to be approximately 100mgHg higher than the maximum 
systolic blood pressure, in most cases 150-170mmHg.119,120 In the clinical setting however, 
when used for regional limb perfusion it is unknown what pressures are achieved with 
rubber tourniquets, and pressures in the vicinity of 300-500mgHg are used with pneumatic 
tourniquets with-out complications.111,119 The optimal duration of vascular isolation for 
regional limb perfusion has not been determined however 30 minutes has been reported to 
be a clinically efficient duration of tourniquet application for the procedure.105,115  
Complications associated with regional limb perfusion occur infrequently. The limitations of 
intravascular regional limb perfusion lie in difficulty of identification of the digital veins if 
swelling is present and vascular thrombosis following repeated catheterisation.113 Transient 
non painful soft tissue swelling has been reported to occur with intra-osseous regional limb 
perfusion; however was found to be self- limiting requiring no further treatment.111,113 The 
use of regional limb perfusion in foals with septic conditions of the tarsi has been associated 
with development of second foci of infection in one report.121  More recently the 
development of osteomyelitis and osteonecrosis of the proximal phalanx was reported as a 
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complication of intra-osseous perfusion of the proximal phalanx with gentamicin, which 
ultimately lead to pathological fracture of the first phalanx and euthanasia of the horse.122 
The dose of gentamicin used for regional limb perfusion in this report was 5mg/kg, a 
substantially higher dose then previously reported for clinical use.117 It is assumed that this 
complication resulted from the dose of gentamicin used, which is consistent with reported 
toxic effects of gentamicin on marrow derived human mesenchymal stem cells at a high 
concentrations, which could compromise the bone-healing process.123 
Antimicrobial regional perfusion is now accepted as part of the standard treatment protocol 
for severe wounds, septic synovial structures and osteomyelitis in the horse. The institution 
of this method of antimicrobial delivery is thought to have contributed to the improved 
success of treatment in equine orthopaedic infections. 
Table 2. Reported use of RLP for treatment of horses with orthopaedic infections 
Site or type of infection  No. horses Age No. of 
RLPs/horse 
Antimicrobial(dose range/RLP) Reference 
  No. 
Distal portion of the limb 24 30 d–24 y 1–9 Gentamicin (100–300 mg) 
Amikacin (125 mg–2 g)  
Ampicillin (9 g) 
 
104,121,124 
Fetlock joint and proximal 
sesamoid bones 
20 3 m–18 y 1–4 Gentamicin (100 mg–1 g) 
Timentin (125 mg–1 g) 
Amikacin (1 g)* 13, 15, 27 
K+Pen (10 X 106 units)* 
 
121,124,125 
Proximal portion of the 
limb 
5 10 d–3 mo 1–3 Gentamicin (100 mg–1 g) 
Amikacin (125–1 g)*  
K+ Pen (106 units)* 
 
104,116,121 
Miscellaneous(septic 
arthritis, Gentamicin (1 g) 
osteomyelitis) 
22 Unspecified 1–4 Amikacin (1–2 g) 
Timentin (1 g)*  
K+Pen (106 units)* 
124,125 
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Distal portion of the limb includes septic processes in hoof, coronary band, pedal laminae, 
phalanges, interphalangeal joints and navicular bursa. Proximal portion of the limb includes 
septic processes in digital flexor tendon sheath, metacarpal bones, metatarsal bones, carpus, 
and tarsus. Fetlock joint refers to metacarpophalangeal or metatarsophalangeal joints. 
*Combined in some cases. 
K+ Pen = Potassium penicillin. 
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Intrasynovial antimicrobial medication: 
Intrasynovial medication with antimicrobials is used widely in equine practice for 
prophylaxis and treatment of septic synovial structures. However is not recommended as a 
sole method treatment for synovial sepsis rather as part of a multimodal approach used in 
combination with arthroscopic debridement, joint lavage and systemic antibiotic therapy. 
The ideal agent has to not only be effective in killing bacteria within the joint, but also not 
infer detrimental effects on the articular cartilage, synovium and surrounding soft tissue 
structures.  
Gentamicin has been extensively studied and found to reach concentrations within the joint 
that far exceed that of systemically administered gentamicin and also achieves significantly 
higher synovial concentrations than that achieved with regional limb perfusion - in the order 
of 800 times the synovial gentamicin concentration.126 The concentration of gentamicin 
within synovial fluid has been shown to be maintained above the MIC for most pathogens 
encountered in equine synovial sepsis for greater then 24 hrs.112 Gentamicin has been shown 
to reduce the pH of synovial fluid in normal horses following intra-articular medication, and 
in horses with synovial sepsis, however contrary to in vitro negative effects of low pH on 
antibacterial activity; this has been shown not to reduce the efficacy of gentamicin in in-vivo 
models of joint sepsis.112 It has been postulated that the reduction in pH of the synovial fluid 
following intra-articular medication may exacerbate bacterial killing due to creating an 
unfavourable environment for bacterial survival.112 Intra-articular administration of 
gentamicin has been shown to consistently produce a mild transient inflammation of the 
synovial membrane which is self-limiting.127 In a canine model gentamicin has been shown 
to passively diffuse across the capillary membrane of normal and osteomyelitic bone.128 
Systemic administration of gentamicin is inadequate for attaining therapeutic concentrations 
of gentamicin within bone.128 Following intra-articular administration of 1g gentamicin the 
concentration of gentamicin within the bones adjacent to the medicated joints were shown to 
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be above MIC for the commonly isolated pathogens of equine orthopaedic infections for 8-
12 hours.126  
Amikacin, also an aminoglycoside, has been reported as the most commonly used 
antimicrobial for intrasynovial medication in horses in north America.129 The efficacy of 
amikacin against a wide range of bacteria implicated in equine orthopaedic infections 
accounts for its widespread use.130 The reported MIC of amikacin for susceptible bacteria 
has been reported to be 4 micrograms/ml,131 which is not only easily surpassed with intra-
articular medication with 500mg of amikacin but is maintained above MIC for 48hours in 
inflamed joints.132 Synovial inflammation has been shown to not only reduce the time for 
which amikacin concentrations remain above the MIC for susceptible isolates,  but also 
reduces the Cmax  attained, compared with non-inflamed joints.
132 This was attributed to the 
increased vascularity of inflamed joints allowing more rapid removal from the joint.132 In the 
same study it was reported that unlike gentamicin, amikacin did not incite any cytological 
evidence of joint inflammation in normal joints.132 
Ceftiofur sodium, a broad spectrum, beta lactamase resistant, third generation cephalosporin 
with bacteriocidal activity has also been investigated for intra-articular use in the horse. 
Unlike gentamicin and amikacin, ceftiofur sodium is classed as a time dependant 
antimicrobial. It has been reported that 150mg of ceftiofur administered via intra-articular 
injection not only achieves Cmax more rapidly but also maintains concentrations higher 
within the synovial compared to intravenous administration of 2.2mg/Kg.133 The 
concentration within synovial fluid remained above the reported MIC of 2ug/ml of most 
susceptible pathogens for up to 24 hours, however this study was performed in horses free of 
musculoskeletal disease therefore this may not be representative of concentrations achieved 
or maintained in inflamed synovial structures.133 Ceftiofur was found to impart minimal 
synovial inflammation, and no significant alterations in articular cartilage or synovium 
morphology.133 
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Doxycycline, a tetracycline antimicrobial that has less interference with calcium binding 
then agents in this group, has also been investigated for direct intra-articular administration 
in a bovine calf model.134 Doxycycline has been shown to have anti-inflammatory and 
chondroprotective properties, thought to be imparted via modulation of inflammatory 
mediators (PGE2 and NO) and reduction in metallomatrix proteinase activity.
135,136 
Medication of healthy calf joints with doxycycline at 5mg and 10mg did not induce any 
adverse effects apart from transient mild synovial inflammation similar to that observed with 
aminoglycosides and cephalosporins, and was therefore concluded to be compatible with the 
synovial tissues.134 Despite these encouraging findings, no other data is present at this time 
regarding the pharmacokinetics of doxycycline as an intra-articular medication in the horse. 
Direct intra-articular injection of synovial spaces has been reported for daily administration 
of a number of antimicrobials including gentamicin, amikacin, and ceftiofur.126 Despite 
resulting in high intrasynovial antimicrobial concentrations it requires daily preparation of 
the overlying skin and repeat trauma to the synovial membrane and capsule.69 Numerous 
methods of direct delivery of gentamicin to the synovial space have been developed apart 
from direct intra-articular needle deposition; these include continuous infusion catheters, 
collagen sponges, and fibrin pads. Continuous infusion of antimicrobials to the synovial 
space yields steady state concentrations in the vicinity of >100 MIC of common isolates of 
equine orthopaedic infections with the advantage of avoiding repeated articular injections, 
articular damage resulting from antimicrobial impregnated beads or there retrieval, and the 
limitations of anatomic locations of regional limb perfusion.137 In early reports on normal 
tarso-crural joints in horses this method of delivery resulted in higher concentrations of 
gentamicin within the synovial fluid, synovial membrane and subchondral bone then that 
achieved by intra-articular injection or by regional limb perfusion.80 The ability for 
continuous delivery of antimicrobials to the synovial space may be more relevant for time 
dependant antimicrobials such as cephalosporins rather then concentration dependant 
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antimicrobials such as gentamicin.69 The continuous presence of the infusion catheter within 
equine joints has been reported to have no effects on histological scores of articular cartilage 
damage or synovial membrane inflammation.138 Despite encouraging results with clinical 
use of this method of delivery it has not been widely instituted in routine management of 
synovial sepsis due to cost and technical difficulties. 
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Case series: Outcome of horses with synovial sepsis treated with local antimicrobial 
therapy at Murdoch University (2007-2010) 
Synovial contamination/sepsis is not an uncommon presentation to the equine veterinarian. 
The condition is recognised, and managed as, a medical emergency due to the potential fatal 
outcome of the disease. Synovial structures – whether it be diarthrodial joints, tendon 
sheaths or bursae, have a similar anatomic and physiologic make up, with a synovial lining 
that produces and maintains the physical, cellular and biochemical environment.5 
Introduction of micro-organisms in to the synovial cavity can occur via a number of means. 
These include direct deposition from trauma to or penetration of the synovial structure, 
extension from perisynovial infection, haematogenous localisation or through iatrogenic 
deposition with surgery or centesis/medication of the structure.5 The virulence and number 
of the contaminating organisms along with the presence of devitalised or traumatised tissue 
and foreign material all predispose the development of infection. 5,139 In young animals 
immunological incompetence is also recognised as a predisposing factor for  the 
development of synovial infection.2,4  
The synovium and articular cartilage undergo progressive destruction due to the combined 
effects of the pathogen toxins and protease release, along with the release and induction of 
free radicals and cartilage degrading proteases by the host immune response.5 Historically 
the development of intrasynovial pannus (fibrocellular conglomerates) has hindered the 
management of the disease and contributed to poor outcomes in horses as it can surround 
foreign material and necrotic debris thereby creating a nidus for persistent infection.140 
Synovial membrane diffusion is impeded by pannus development, resulting not only in 
synovial malnutrition but also impaired delivery of antimicrobials to the synovial 
structure.140 The objectives of therapy include debridement of foreign material, debridement 
of contaminated/infected tissue, removal of micro-organisms, removal of destructive 
enzymes and radicals, promotion of healing tissue and restoration of a normal synovial 
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environment.140 Outcomes from endoscopic surgical management of contaminated and 
infected synovial structures followed by a combination of systemic and local antimicrobial 
therapy have been reported by a number of authors.31,53,141-145 Survival rates of 65%-90% 
following endoscopic debridement and antibiotic therapy have been reported, with 54-94% 
of animals returning to preoperative level of performance.10,140,146-148 Admission to a hospital 
greater then 24 hours after contamination of a synovial structure has been previously shown 
to significantly increase the risk of development of synovial sepsis and significantly increase 
the risk of non-survival.141 The presence of marked pannus, regional intravenous 
antimicrobial therapy and systemic antimicrobial therapy for greater then 7 days have also 
been associated with non-survival and reduced postoperative performance.10 
Local antimicrobial therapy has been advocated to obtain high local antimicrobial 
concentrations whilst avoiding systemic toxicity.50 Both intravenous regional limb perfusion 
and synovial administration of antimicrobials have been reported for the management of 
contaminated and infected synovial structures.10,105,112,143 This case series describes the 
outcomes of 44 patients with contaminated or infected synovial structures, treated with 
endoscopic lavage and debridement, along with systemic and local antimicrobial therapy.  
The hypothesis of this study is that the success of treatment of septic synovial structures with 
local antimicrobial therapy would be consistent with earlier reports. 
Materials and Methods: 
Horses: 
Medical records (2007-2010) of horses which received endoscopic lavage and debridement 
of a synovial structure for management of synovial contamination or infection were 
reviewed. Synoviocentesis was attempted in all cases. In cases where a sample could not be 
collected and a wound was present, distension of the synovial cavity was undertaken to 
detect communication between the wound and the synovial cavity. A synovial cavity was 
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classed infected if synoviocentesis yielded samples in which the differential neutrophil count 
was greater then 80% and infected or contaminated if communication of the synovial cavity 
with a wound could be demonstrated via synovial cavity distension with sterile saline. 
Patients less than 12 weeks of age were excluded. Only cases where endoscopic lavage and 
debridement were undertaken were included.  Data retrieved included signalment, degree of 
lameness, time and cause of synovial injury, structures involved, time to referral, if a 
positive culture was obtained, method of local antimicrobial administration and number of 
local antimicrobial treatments, number of subsequent synovial lavages following initial 
endoscopic lavage, synovial culture results, synovial differential cell counts and total solids, 
synovial cytology, time to discharge. 
Outcome: 
Short term success was defined as survival to discharge. Long term follow up was obtained 
via telephone questionnaire of owners, referring veterinarians or trainers at least 6 months. 
Successful long term outcomes were defined as return to equal or better performance, or 
they were sound however retired for other reasons. Horses remaining lame were classed as 
unsuccessful.  
Results: Forty four horses met the inclusion criteria. The mean age was 5.5 years STD , 
(range 3 months – 16 years). There were eight entire males, 21 females, and 15 geldings. 
The majority of the population was made up of thoroughbreds (23), the rest of the 
population was comprised of a mixture of breds; warmblood (5), quarter horse (5), 
standardbred (4), Arabian (3), crossbred (2), whaler (1) and paint horse (1). 
Thirty five horses (79.5%) sustained wounds which resulted in synovial sepsis, 5 horses 
(11.3%) were classed as iatrogenic synovial sepsis developing synovial sepsis following 
surgery or intra-articular medication. Three horses (6.8%) developed infection following 
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local extension from a foot abscess, and in one (2%) horse the origin of infection is 
unknown. 
Forty seven synovial cavities were involved in the 44 horses which met the inclusion  
criteria. The synovial cavities involved were as follows: metacarpophalangeal joint (9); 
digfital tendon sheath (9); tibiotarsal joint (6); femoropatella joint (5); middle carpal joint 
(4); distal interphalangeal joint (3); navicula bursa (2); extensor radialis tendon sheath (2); 
cuboidal joint (1); scapulohumeral joint (1). Of the 44 horses 24 (55%) had a single joint 
involved; 15 (34%) had a single bursa or sheath involved; and 5 (11%) horses had multiple 
structures involved. Of the 44 horses, the time to referral was available for 43 horses; with 
20 horses (47%) being referred within 24 hours, 8 horses (19%) referred with-in 1-7days of 
onset of disease and 15 horses (34%) being referred for further examination and 
management greater than 7days after onset of disease. 
Of the forty-four horses, a synovial fluid sample was collected from 37 cases. Cytology was 
performed on all 37 synovial fluid samples: one horse had a normal percentage of 
neutrophils (<10%); six horses had a moderate increase in percentage of neutrophils (10-
80%); and thirty had a marked increase in percentage of neutrophils (>80%). The average 
white cell count was recorded for thirty six samples was 56.94 +/- 66.05 x109 cells/L(range 
0.3-338x109 cells/L) of which 6 horses (17%) had a normal total nucleated count (<5x109 
cells/L). The average total solids of the 36 synovial fluid sample which were recorded was 
54.84 +/- 20.56 mg/DL (range 10-112mg/DL), with one horse having normal total solids 
(<20mg/DL), seven horses having a moderate increase (20-40mg/DL) and 28 having marked 
increase in total solids (>40mg/DL). Of the thirty seven samples collected, 32 had synovial 
fluid submitted for culture. Of these only 12 (38%) yielded a positive culture result.  
All horses received at least one endoscopic lavage and debridement of the synovial cavity. 
All endoscope portals were closed with simple interrupted 2-0 polypropylene sutures. Where 
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a subcutaneous layer was required wounds were closed with a simple continuous layer of 2-
0 polyglactin 910 in the subcutaneous tissue, and all skin wound were closed with a 
combination of tension relieving near-far-far-near sutures or vertical mattress sutures of no 2 
polydioxanone and then apposition of the skin edges with simple interrupted sutures of 2-0 
nylon. Twenty-six horses (59%) had one or more subsequent through and through lavage of 
the synovial cavity via 18 or 16 gauge needles.  
All horses received systemic antibiotics, which consisted initially of procaine penicillin and 
gentamicin and then was modified if culture results indicated alternate sensitivity patterns. 
All horses that had involvement of structures distal to the crus or gaskin had sterile primary 
dressings applied over the surgical wound closures and then supported by a heavy cotton 
wool bandage. In all cases the bandage was changed 24 hours following surgery to assess 
wound drainage and then bandage changes occurred every 48 hours at which time 
synoviocentesis followed either synovial medication or intravenous regional limb perfusion 
were undertaken. Twenty-one of the horses (48%) received intrasynovial antibiotics as a sole 
method of local antimicrobial delivery every 48 hours, four (9%) received intravenous 
regional limb perfusion as a sole method of local antimicrobial therapy every 48 hours, and 
19 horses (43%) received a combination of intrasynovial medication and intravenous 
regional limb perfusion with protocol varying between cases and clinician preference.  All 
horses received phenylbutazone 2.2mg/kg orally twice daily initially and then reduced to 
once daily and then ceased at the discretion of the attending clinician. 
Forty two (95%) of the 44 horses were successfully discharged from hospital, two (5%) 
horses were euthanized prior to discharge as they were unresponsive to therapy. The average 
duration of hospitalisation was 14.9 days (range 3-90 days). Eleven horses (26%) were 
discharged less than 7 days after admittance; 16 horses (38%) were discharge between 7 and 
15 days following admittance; and 15 horses (36%) were discharged more than 15 days 
following admittance.  Of the 42 horses discharged from hospital, follow up information was 
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available for 41 horses. Of these, 33 horses were sound (78%) more than six months 
following discharge, with 54% (18) of these horses returning to their preoperative 
performance level.  Eight horses (19%) remained lame and one horse was lost to follow up. 
Of the horses with a single joint involved 19 of 24 (36.5%) were sound six months after 
discharge; 11 of the 15 (73%) horses with a single bursa or sheath involved were sound six 
months following discharge; and three of five horses (60%) with multiple structures returned 
to soundness six months following discharge. Of the horses that received intra-articular 
administration of antimicrobials alone 15out of 19 (79%) were sound six months following 
discharge; those receiving intravenous regional limb perfusion alone 3 of 4 were sound at 
follow up; and 15 of 19 (79%) of those receiving a combination of intrasynovial and 
intravenous regional limb perfusion were sound at follow up. Of the 43 horse for which time 
to referral was available, 16out of 20 (80%) were referred within 24 hours were sound at six 
months; 6 out of 8 (75%) that were referred between 1-7days were sound; and 11 out of15 
(73%) that were referred greater than 7 days after onset of disease were sound more than six 
months following discharge. 
Discussion: 
The population in this case series reflects that of past reports, with a predominantly 
Thoroughbred population.10,147 The majority of contaminated and infected synovial 
structures were due to involvement of the structure in a traumatic wound, which is also 
consistent with the report by Wright in 200310, however the incidence of wounds in the 
pathogenesis of septic synovial cavities is far greater than that reported by Schneider et al in 
1992.30  
Forty-two of the forty-four horses survived to discharge leading to a short term success rate 
of 95%, which is higher than the 90% success rate reported by Wright et al 200310 and the 
85% short term success rate reported for adult horses by Schneider in 199230 however the 
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population in the two latter studies was more than three times the size of the present case 
series. The long term success rate in the present case series was 78%, with 54% of these 
horses returning to their preoperative performance level. The successful return to 
preoperative performance levels in the present series is comparable to that reported by 
Schneider et al 1992 (56.5%), however are far inferior to the 81% return to preoperative 
performance that was more recently reported by Wright et al 2003. The reason for such a 
reduced successful return to preoperative performance cannot be determined in this study as 
factors that have been previously found to heavily influence long term return to sound-ness, 
such as the presence of osteochondral lesions and the presence of marked pannus,10 were not 
assessed in this case series. 
Endoscopic examination, lavage, and debridement were performed in all cases in this series. 
Endoscopy permits thorough evaluation of the synovial cavity whilst simultaneously 
allowing for removal of foreign material and infected and devitalised tissue.53,149 Visually 
directed lavage of the synovial cavity can also be undertaken which is thought to aid in 
removal of free floating debris, debulk micro-organisms and remove destructive radicals and 
enzymes.145 As in previous reports all patients were managed in a way that facilitated 
effective surgical debridement of the synovial cavity and conversion from a contaminated or 
infected structure to that of a clean-contaminated structure that could be closed safely. This 
was based on prior reports that endoscopic surgery is capable of thoroughly cleansing the 
synovial cavity, and that closure of wounds would prevent ongoing contamination of tissue 
and secondary infection.10  
The average length of hospitalisation in the current series was 14.9 days (range 3-90 days), 
which is less the 18 days (range 6-71 days) that was reported by Wright et al in 200310 and 
the 21 days reported by Schneider et al 1992.30 
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Infected synovial structures as a result of a traumatic wound are likely to have multiple 
bacterial species involved.30  Based on previous reports of bacterial isolates 30,47,48 and the 
reported sensitivity patterns 47,48 with suggested synergism between penicillin and 
gentamicin all horses were initially started on a course of procaine penicillin and gentamicin. 
All horses received this antimicrobial regime until the clinically sound and had normal 
synovial fluid parameters or a culture and sensitivity result indicated resistance of the 
offending organism was present. 
This study has many limitations, with major limitation being that of a small number of cases 
meeting the inclusion criteria. This restricted the statistical analysis to descriptive statistics 
alone, as there were too few cases with a variety of synovial structures involved, to allow 
meaningful statistical analysis of the impact of local antimicrobial therapy on the outcomes 
of therapy of such cases. 
As opposed to previous reports where local antimicrobial therapy was only instituted in 
selected cases 10and carried an association with non-survival and reduced postoperative 
performance10, all cases in this series underwent some form of local antimicrobial 
administration and was therefore  not associated with a poor prognosis or reduced return to 
function.  The success of therapy in this case series is comparable to previous reports, and 
supports the use of local antimicrobial therapy in management of septic synovial structures 
in the horse.  A case controlled prospective study would be required to assess the impact the 
institution of routine local antimicrobial therapy alone on short and long term success for 
horses with septic synovial structures. 
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Biodegradable antimicrobial impregnated implants: 
Gentamicin impregnated collagen sponge 
Commercially available gentamicin impregnated collagen sponge have been used in dogs, 
cattle and horses.150-154 Purified collagen type one has been used as a vehicle for 
antimicrobial delivery due to its inherent biocompatibility, low antigenicity and 
biodegradability.155,156 The collagen protein is highly conserved between species, such that 
manufactured carrier biomaterials (films, gels, sponges) from purified animal and 
recombinant sources of type one collagen impart low immunogenicity.155 A study in healthy 
adult rabbits where gentamicin impregnated collagen sponges were implanted into the 
medullary canal of the femur revealed local bone gentamicin concentrations remained above 
MIC and systemic gentamicin concentrations remained below which toxicity occurs for 
greater then 28 days.157 Gentamicin impregnated collagen sponges have been used 
extensively and successfully for prophylaxis against the development discospondylitis in 
humans undergoing discectomy procedures.158 Achieving therapeutic concentrations of 
antimicrobial in the disc space is of concern with systemic antimicrobial administration due 
to disc vasculature declining from birth until the end of the second decade, where it remains 
that only the periphery of the disc’s remain vascularised.158 Gentamicin impregnated 
collagen sponges have been shown to provide high local antimicrobial concentrations above 
MIC for more than 7 days following implantation into soft tissue.156 Gentamicin 
impregnated collagen sponges have been reported in the veterinary literature in the 
successful treatment of discospondylitis in a two year old boxer dog.154   
Implantation of gentamicin impregnated collagen sponges in to the tarsocrural joints of 
horses revealed that gentamicin rapidly eluted from the collagen sponge reaching Cmax 
within 3 hours and then rapidly decreasing, at a rate comparable to that of clearance of 
gentamicin from direct injection.159,160 Rapid elution attaining initial high Cmax followed by 
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suddenly decreasing concentrations of gentamicin was also reported in human trials of 
gentamicin impregnated collagen sponges in people with chronic osteomyelitis.161 Only 
minimal inflammatory changes were observed in horses that underwent implantation of 
gentamicin impregnated collagen sponges in the tarsocrural joint however these changes 
could not be differentiated between that induced by gentamicin alone; and that potentially 
imparted from the collagen sponge.159 Despite only minor histological inflammatory changes 
in the synovial fluid an acute onset of lameness and periarticular swelling consistently 
developed at 12 hours post insertion of the implant.159 The study of this delivery modality in 
the tarsocrural joint of the horses concluded that gentamicin impregnated collagen sponges 
did not offer any advantage over direct intra-articular medication of the joint.159 
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Calcium sulphate 
Calcium sulphate, commonly known as Plaster of Paris, has been used since 1892 to fill 
bone defects and to act as a bone graft substitute.162 Calcium sulphate is a biodegradable 
substance, with relatively rapid resorption characteristics that may result in more complete 
elution of antimicrobials; along with osteoconductive properties - promoting new bone 
formation in the contained defects.163 Significant resorption of implanted calcium sulphate 
and replacement with new bone formation has been shown to occur in 6 weeks in a number 
of animal models of osteomyelitis.164,165  Medical grade calcium sulphate is a relatively pure 
alpha hemihydrate crystal that hardens with hydration.166 Water soluble antimicrobials can 
be incorporated into the crystalline structure of the calcium sulphate hemihydrate matrix, 
thereby impregnating the implant.163 Calcium sulphate has been shown to remain cohesive 
with up to 12% weight of antibiotic loading.82 The bio-ceramic properties of calcium 
sulphate imparting full resorption imply that all antimicrobial impregnated in the implant 
should be delivered to the local tissues.163 As the calcium sulphate is resorbed by the body, it 
does not require a second procedure to remove the implant.163 Calcium sulphate is reported 
to be well tolerated by the body, non-immunogenic, and fully biodegradable.166 
The rate of resorption of the calcium sulphate has been found to be proportional to the 
density of the crystal, thereby imparting slow or rapid resorptive characteristics determined 
by the method in which it is produced.166 Tobramycin impregnated calcium sulphate beads 
have undergone considerable research in animal models of osteomyelitis 165,167,168 and have 
also been used successfully in clinical cases of chronic osteomyelitis in people.166,169 
Tobramycin has been shown to elute from calcium sulphate beads providing therapeutic 
local concentrations for up to 28 days whilst maintaining non-toxic serum levels.163 Even 
when used in a canine model to provide 1.8 times the maximum prescribed human dose, 
serum tobramycin levels fell below detectable levels within 24 hours.163,165 Tobramycin 
impregnated bone pellets have been shown to be safe and effective methods of local 
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administration of antimicrobials and dead space management in animal models of 
osteomyelitis and contaminated open fractures.163 Calcium sulphate pellets containing 2%, 
4% and 10% tobramycin used in a canine humeral model have all revealed similar 
antimicrobial release profiles, with systemic serum concentrations falling below detectable 
levels within 24 hours.163 However local osseous and soft tissue concentrations were 
maintained within therapeutic range for 7 days.165 In dogs with clinical osteomyelitis 
following tibial plateau levelling osteotomy procedures, tobramycin impregnated calcium 
sulphate beads were used for successful treatment in conjunction with surgical debridement; 
and were found to be radiographically unapparent within 5 weeks.170 
In vitro trials of gentamicin impregnated calcium sulphate placed in porcine serum reported 
elution of 80% of the total gentamicin within the bead in the initial 48 hours, and continued 
to release gentamicin at lower levels, however still at concentrations that inhibited E.coli 
growth for the 14 day duration of the study.171 The persistent low concentration after the 
initial peak concentration, achieved at 48 hours, may not achieve concentrations that are 
bactericidal for all pathogens encountered in equine orthopaedic infections and therefore 
may not be sufficient for use in the horse; rather may be better suited for prophylaxis of 
infection following orthopaedic surgery in the horse.171  
Elution pharmacokinetics have been described for gentamicin, vancomycin, teicoplanin and 
clindamycin from calcium sulphate beads, revealing a high initial release of antimicrobial in 
the first 24 hours (45% and 80% of the total glycopeptide and gentamicin/clindamycin 
respectively in the initial 24 hours) and then a sustained lower rate of release over the 
following 10 days.172 Doubling the concentration of the antimicrobial contained within the 
bead resulted in a higher initial antimicrobial release, and a more prolonged two-fold 
increase in antimicrobial elution in the second phase of elution.172 
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Conventional calcium sulphate implants remain present in the tissue following the initial 
rapid elution of impregnated antimicrobials; this has been shown to provide a surface for 
bacterial adhesion and thereby allow establishment of infection.173 In an effort to prevent 
musculoskeletal infection following trauma, conventional calcium sulphate implants which 
resorb at the same rate as new bone forms, have been modified to rapidly resorb; thereby 
completely eluting impregnated antimicrobials locally leading to high concentrations of 
antimicrobial over a short period of time.82  A variation in the crystal structure and therefore 
surface area of the pellets allow for the rapid dissolution of impregnated antibiotics and 
pellet resorption.82 The amikacin, gentamicin and vancomycin elution from rapidly 
dissolving calcium sulphate pellets has been reported as follows: 50-70% of the antibiotic 
elutes in the first 4 hours, 85-90% by 8 hours, and over 95% by 12 hours, with pellets 
completely dissolved within 16 hours.82 Amikacin impregnated rapidly resorbing calcium 
sulphate pellets were shown to significantly reduce infection rate distal limb wounds in a 
goat model.174 
Calcium sulphate has been reported to incite a transient cytotoxic effect in humans leading 
to a sterile self-limiting benign inflammatory reaction which responds well to anti-
inflammatory medication.175-177 The uniformity and shape of the crystalline nature of 
purified medical grade calcium sulphate imparts the predictable resorption rate in vivo162; 
however this may also allow for accelerated graft resorption and accumulation of calcium 
rich  fluid which is believed to be responsible for the inflammatory response.177 Others have 
postulated that the occasional serous drainage associated with the calcium sulphate implants 
is due to an osmotic effect of the implant.175   
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In vitro elution characteristics of amikacin from commercially available calcium 
sulphate beads 
P G Harding BVSc (Hons) MACVSa*, RL Smith BVSc (Dist)PGDipVCS MACVS DACVSb 
and GD Lester BSc(Hons) BVMS PhD DACVIMc 
a,b,cDepartment of Equine Medicine and Surgery, Murdoch University, 90 south street, 
Murdoch, Western Australia, 6159, *p.harding@murdoch.edu.au 
Objective: To describe the in vitro elution characteristics of amikacin from 
commercially available antibiotic-impregnated calcium sulphate 
hemihydrate and dextran sulphate beads placed in phosphate-buffered saline 
or equine plasma, and to observe the rate of implant dissolution in saline or 
plasma. 
Study Design: Experimental study 
Methods: Commercially available calcium sulphate hemihydrate-dextran sulphate 
beads impregnated with amikacin sulphate and clindamycin hydrochloride 
were incubated at 37oC in plastic test tubes containing sterile phosphate-
buffered saline (PBS) or equine plasma. The eluent surrounding the bead 
was collected and completely refreshed with drug free sterile phosphate 
buffered saline or equine plasma at predetermined time points. 
Antimicrobial levels were measured in the eluent using liquid 
chromatography-mass spectrometry. 
Results:  Antimicrobial release from the beads followed a biphasic elution pattern 
with an initial rapid release followed by a slower phase. In saline the 
antimicrobial concentration fell below the lowest measurable concentration 
in saline (0.5ug/ml) within 12hours, whereas in equine plasma the 
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antimicrobial concentration fell below the lowest measurable concentration 
in plasma (2ug/ml) within 6 hours.  The beads had completely dissolved in 
PBS by 72 hours whereas in plasma only partial dissolution of the beads 
was noted throughout the 28 days of the experiment. 
Conclusion:  Amikacin eluted rapidly from the commercially available antibiotic-
impregnated calcium sulphate hemihydrate– dextran sulphate beads in 
phosphate buffered saline and fell below 4 ug/ml within 6 hours. The rate of 
bio-implant dissolution was consistently slower in equine plasma compared 
to that in phosphate-buffered saline.   
Key words: local antimicrobial therapy; calcium sulphate; amikacin 
Abbreviations 
PBS Phosphate buffered saline; PMMA polymethylmethacrylate; LC-MS/MS liquid 
chromatography tandom mass spectrometry; MIC minimum inhibitory concentration; Cmax 
maximum serum concentration; 
Introduction 
The development of antimicrobial resistance is a major concern in human and in veterinary 
orthopaedic surgery and wound management.17,48,178 Contaminated wounds involving trauma 
to deep soft tissue structures and exposed bone surfaces occur commonly in equine practice 
often resulting in deep soft tissue infections, local osteitis, and rarely osteomyelitis.27,179 
Therapy usually involves a combination of surgical and medical therapy aimed at removal of 
gross contamination, devitalised tissue and micro-organisms, the promotion of soft tissue 
healing, and restoring function of the soft tissues and bone.50,180 Where bone and deep soft 
tissue structures are infected systemic antimicrobial therapy alone is often ineffective at 
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obtaining a satisfactory outcome due to the inability to achieve high concentrations of 
antimicrobials at the site of infection.27  
Following the successful use of bio-implants in human orthopaedic infections, similar 
therapy is now beginning to be utilized in equine practice. These implants provide a means 
of delivering high concentrations of antimicrobials at the site of infection while avoiding 
possible toxic side effects associated with high systemic concentrations.27,181  Antimicrobial 
impregnated polymethylmethacryalte (PMMA) has been, and remains the most widely used 
antimicrobial impregnated implant in equine practice.27 These implants have resulted in 
improved outcomes for horses with osteomyelitis when compared to the use of systemic 
antimicrobials alone. 88,182 The prophylactic use of antimicrobial impregnated PMMA in 
human joint prosthesis has resulted in as much as a 34% decrease in infection rates.88,89  
Despite the success of PMMA as a carrier for delivery of local antimicrobials there are 
potential problems associated with this chemical compound.  PMMA is poorly 
biodegradable often necessitating an additional surgery to remove the implants 153 and 
therefore creating unwanted dead space.90 If the beads are left in situ there is risk of 
persistent antimicrobial residues for months to years that may potentiate antimicrobial 
resistance. 183 Ironically if left in place the PMMA may act as a nidus for infection after 
antimicrobial elution has reduced below therapeutic levels.184  Finally the construction 
process of PMMA involves an exothermic reaction that has detrimental effects on heat 
sensitive antimicrobials and produces toxic substances.185,186,187  
The development of the ideal antimicrobial delivery system for use in therapy of orthopaedic 
sepsis continues to be the focus of on-going research.  The aim has been to develop a system 
that is biodegradable, does not evoke an inflammatory response, has no detrimental effects 
on the antimicrobials during the construction process, and is capable of sustaining release of 
the antimicrobials at appropriate therapeutic concentrations for a sustained period.69,181 
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Alternatives to PMMA have included antimicrobial impregnated collagen sponges, which 
despite good success in an experimental equine septic arthritis model152, was demonstrated 
to rapidly elute gentamicin in the tarsocrural joint in the horse, dropping well below 
therapeutic levels within 48 hours.159 Ferric-hyaluronate loaded with amikacin has also been 
assessed in vitro and in vivo in equine joints and also failed to provide prolonged 
antimicrobial release.188 Calcium sulphate hemihydrate  (plaster of Paris) has also been used 
as a carrier for antimicrobials and could be an ideal local delivery system suitable for both 
soft tissue and osseous infections.166,167,189,190 The compound is absorbable, osteoconductive 
in the presence of osseous tissue but evokes no bone formation in the absence of periosteum 
or bone. Reports of the in vitro elution profiles of antimicrobial from antimicrobial 
impregnated calcium sulphate hemihydrate beads have provided consistent results of initial 
rapid elution of antimicrobials followed by a prolonged slower phase of drug release. 
171,191,192 
The objective of this study was to examine the elution characteristics of a commercially 
available pre-prepared antimicrobial impregnated calcium sulphate hemihydrate – dextran 
sulphate bead. Our hypotheses were: (1) amikacin elution would result in concentrations that 
remain above 4 ug/ml, the reported MIC for common equine pathogens, for a prolonged 
period; (2) there would be no difference in elution of amikacin from beads placed in saline 
and in equine plasma; and (3) there would be no difference in the rate of dissolution of the 
calcium sulphate hemihydrate – dextran sulphate when the beads were placed in phosphate 
buffered saline compared to those placed in plasma. 
 Materials and Methods 
Amikacin concentrations were measured using liquid chromatography tandem mass 
spectrometry (LC-MS/MS). The lower limit for detection of concentrations of amikacin in 
phosphate buffered saline was 0.5 ug/ml. The method was less efficient in detecting 
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amikacin in plasma when low concentrations were present. The lowest concentration that 
amikacin could be detected accurately in plasma by the LC-MS method was 2.0 ug/ml.  
Six commercially available calcium sulphate hemihyrate-dextran sulphate beads 
impregnated with amikacin and clindamycin (Matrix III Antibiotic Beads TM, Royer Animal 
Health, Frederick, Maryland) were placed individually in to sterile plastic test tubes. The 
manufacturer label claims a mean bead weight was 23mg, containing a standardised 3.2% 
amikacin (0.736 mg amikacin/bead) and 1.6% clindamycin (0.368 mg clindamycin/bead) 
with a mean sphere diameter of 3mm. The weight and diameter of the individual beads were 
not measured prior to undertaking the experiment. Two series of assays, one series in PBS 
and one series in equine plasma, were undertaken simultaneously over the following 28 days 
to establish the amikacin elution profiles from the beads. Three calcium sulphate 
hemihydrate-dextran sulphate beads were each placed individually in 3ml of PBS, and three 
beads were placed individually in 3mls of commercial equine plasma and incubated at 370C. 
At predetermined sample times (3hrs, 6hrs, 12hrs, 24 hours, 48hrs, 72hrs, 5days, 7days, 
14days and 28 days) the PBS and plasma samples were inspected grossly to determine if the 
beads had completely eroded. Following visual inspection if the bead had not completely 
eroded then the entire volume of eluent was collected from the tube and refreshed with 3 ml 
of the same drug free fluid, either PBS or plasma. Following refreshment of the eluent, the 
tubes containing the beads were inverted 15 times before replacement in the incubator at 37-
0C.The eluent samples were then labelled and stored at -20 degree Celsius until antimicrobial 
assay using LC-MS.  
Amikacin in saline sample preparation 
Saline samples and calibration standards were diluted 1:1 with 1% formic acid in acetonitrile 
and filtered at 0.45 um. Quality control spikes were prepared by spiking ultra pure water 
with amikacin at 0.5, 1, 2, 10 ug/ml, which were then processed as for the samples.  
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In order to determine sample concentrations where calculated concentrations exceeded the 
calibration range of 0.5 to 10 ug/ml , samples were diluted a further 1:10 with 50% 
acetonitrile/1% formic acid in ultra pure water. Further quality control spikes were prepared 
at 10, 50, 20 and 100ug/ml, and were diluted a further 1:10 with 50% acetonitrile/formic 
acid as for diluted samples.  Calibration standards at 0.5, 0.8, 1, 1.5, 2, 5, 10, 20 ug/ml 
amikacin were diluted 1:1 in 50% acetonitrile/1% formic acid in ultra pure water.  
Amikacin in plasma sample preparation 
Plasma samples were protein-precipitated with 4 volumes of acetonitrile/1% formic acid and 
centrifuged. A portion (portion A) of the supernatant was evaporated to dryness under 
nitrogen, reconstituted in one-fifth volume of 50% acetonitrile/1% formic acid.   
A second portion (portion B) of the supernatant was diluted with one volume of 50% 
acetonitrile/1% formic acid. Portion B was used to determine amikacin content for samples 
exceeding the calibration range for analysis of Portion A preparations. Matrix-matched 
calibration standards were prepared from blank plasma extracts spiked at 0.5, 0.8, 1, 1.5, 2, 
5, 10, 20 ug/ml amikacin. 
Instrumental methods 
Sample volumes of 40 uL were chromatographically separated on an Agilent 1200 liquid 
chromatography system with an Atlantis  HILIC Silica 4.6 x 150 mm column of 5 um 
particle size. The mobile phase consisted of 5 mM ammonium formate at pH 2.5 (A) and 1% 
formic acid in acetonitrile (B), pumped at a gradient of 10% to 50% A buffer at 0.5 ml/min. 
Instrument responses for transitions m/z = 586.4 to 163.1 and m/z = 586.4 to 264.2 were 
monitored on an AB SCIEX 4000 QTRAP tandem mass spectrometry system used in the 
positive electrospray ionization mode. 
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Liquid chromatography-tandem mass spectrometry (LC-MS/MS) data for saline samples 
were processed using Anlayst 1.5 (AB SCIEX) by integrating the peak area for the m/z = 
586.4 to 163.1 against calibration standards. 
Results 
Amikacin eluted rapidly from the beads in PBS falling below the lower limit of detection 
within 12 hours, and remained below the lower limit of detection thereafter until complete 
bead dissolution occurred between 48 and 72 hours. This finding was consistent across all 
three assays. Amikacin eluted rapidly from the beads in plasma and fell below the lower 
limit of detection in plasma within 6 hours. The calcium sulphate hemihydrate- dextran 
sulphate beads eroded at a far slower rate, with no complete bead dissolution in equine 
plasma occurring throughout the 28 days of the study. 
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Table 1. Amount of amikacin eluted (ug/ml) in phosphate buffered saline 
Time Assay 1 Assay 2  Assay 3 Average 
Standard 
deviations 
1hr 100 82 100 94 10.39230485 
3hr 21 18 19 19.3 1.527525232 
6hr 3.2 1.7 3.4 2.8 0.929157324 
12hr <0.5 <0.5 <0.5 <0.5  
24hr <0.5 <0.5 <0.5 <0.5  
48hr <0.5 <0.5 <0.5 <0.5  
72hr <0.5 <0.5 <0.5 <0.5   
Table 2. Amount of amikacin eluted per bead (ug/ml) in equine plasma 
Time Assay 1 Assay 2  Assay 3 Average 
Standard 
deviations 
1hr 13 13 14 13.3 0.577350269 
3hr 4.6 5.5 5.6 5.2 0.550757055 
6hr <2.0 <2.0 <2.0 <2.0  
12hr <2.0 <2.0 <2.0 <2.0  
24hr <2.0 <2.0 <2.0 <2.0  
48hr <2.0 <2.0 <2.0 <2.0  
72hr <2.0 <2.0 <2.0 <2.0  
120hr <2.0 <2.0 <2.0 <2.0  
168hr <2.0 <2.0 <2.0 <2.0  
336hr <2.0 <2.0 <2.0 <2.0  
504hr <2.0 <2.0 <2.0 <2.0  
672hr <2.0 <2.0 <2.0 <2.0   
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Discussion 
The results of this study have shown that amikacin elutes rapidly from the calcium sulphate 
hemihydrate dextran sulphate beads in PBS, consistently falling reported MIC of most 
pathogens encountered in equine orthopaedic infections of 4ug/ml47 within 6 hours. There by 
disproving our first hypothesis that amikacin elution would result in concentrations that 
remain above 4 ug/ml, the reported MIC for common equine pathogens, for a prolonged 
period. 
Amikacin is an aminoglycoside antimicrobial, the rate and extent of bacterial kill is related 
to attainment of a high maximum serum concentration (Cmax) in relation to the minimum 
inhibitory concentration (MIC), which ideally should be ≥ 8-10 ug/ml.193 The reported MIC 
for most pathogens encountered in equine orthopaedic infection is 4 ug/ml,47 hence it would 
be desirable to achieve initial local concentrations of amikacin of 32-40 ug/ml. In phosphate 
buffered saline the concentration of amikacin initially peaked at (average C(max) – 100ug/ml) 
at 1hr in phosphate buffered saline, approximately 25 times the reported MIC for equine 
pathogens however elution slowed quickly to produce concentrations that were below MIC 
at 6 hours. The elution characteristics of the amikacin from this bio-implant in phosphate 
buffered saline is in agreement with earlier in vitro reports of antimicrobial elution from 
calcium sulphate based implants, where an initial rapid elution occurred followed by a 
prolonged slower rate of elution.191,192,194 If the elution of amikacin from the bio-implant 
occurs in a similar fashion in vivo, then it offers no advantage in the clinical setting over 
other local delivery systems such as intra-articular or intravenous regional limb perfusion, 
which have been reported to achieve initial high concentrations and  also maintain local 
osseous concentrations of gentamicin sulphate above MIC for 8 hours in the horse, along 
with a relative ease of administration and lower cost.126  
 Page 64 
 
Local antimicrobial therapy is commonly used in equine practice for musculoskeletal 
wounds and infections. When used prophylactically with orthopaedic implants or used 
therapeutically in the presence of infection, local antimicrobial therapy aims to deliver active 
antimicrobial to the site of infection, at concentrations that exceed the MIC for offending 
pathogens for a therapeutically relevant period of time.195 This not only alleviates the risk of 
systemic toxicity, but results in local concentrations far superior to that which can be 
achieved from systemic dosing at a reduced cost and without adversely impacting dead 
space management. Given the growing concerns in human and veterinary medicine of 
antimicrobial resistance, avoidance of sub-therapeutic antimicrobial concentrations in the 
management of infection is a priority. 
Using the methodology as described we were unable to account for the total amount of drug 
that was reportedly present in the bead. Possible explanations could include problems with 
the experimental design, analytical technique, or inadequate drug within the bead. 
Preliminary studies using the LC-MS/MS technique revealed that this methodology was 
highly accurate in detecting amikacin in spiked PBS samples to a lower limit of detection of 
0.5 ug/ml. As these beads were manufactured from an external commercial source we were 
unable to verify the amount of drug present in each bead.  
Our finding that amikacin eluted rapidly from the calcium sulphate hemihydrate dextran 
sulphate bead in PBS is consistent with the findings of others investigating the elution 
characteristics of antimicrobials from calcium sulphate based implants.192,196,197 
Manufacturers of the implant used in the current study claim that the inorganic/polymer 
composite provides an innovative drug delivery matrix which has a highly-controllable 
release profile and dissolution rate. The findings in this study would suggest that this is not 
the case in PBS, however the dissolution of the implant was noted to be substantially slower 
in plasma and controlled drug delivery and bead dissolution may therefore hold true in vivo. 
Contrary to in vitro findings, it has been recognised in vivo that elution of tobramycin from 
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calcium sulphate based bio-implants for the treatment of experimentally induced 
osteomyelitis in rabbits has resulted in significantly slower and more prolonged elution of 
the antimicrobial thereby maintaining a therapeutic concentrations within local tissues for 7 
days,165 further to this tobramycin impregnated calcium sulphate based bio-implants have 
been successfully used in combination with surgical debridement clinically in chronic 
osteomyelitis in humans.167 The difference in findings between in vitro and in vivo findings 
could indicate a problem in experimental design, and that the PBS model may not be ideal 
for the in vitro assessment of bio-implant antimicrobial elution characteristics. We chose this 
model because it has been widely used, and is an accepted model, to characterise the elution 
patterns of antimicrobials from implants.82,94,96,192,196,197  Whilst it may not allow accurate 
assessment of antimicrobial elution in vivo, it does allow comparison of antimicrobial 
elution from implants with differing formulations and substances. 
A media that better reflects the in vivo environment may provide a more accurate 
representation of the in vivo elution characteristics when studied in vitro. Elution 
characteristics within equine plasma may be more reflective of that in vivo as compared to 
the PBS, and may be a more reliable model for in vitro assessment of elution characteristics 
of antimicrobials from bio-implants. In an effort to overcome the shortfalls of using PBS, we 
chose to undertake a simultaneous elution study in equine plasma to observe for any 
difference in the elution characteristics of amikacin from this bio-implant. The use of equine 
plasma as a media for antimicrobial elution studies has not been reported thus far. In 
validating the analytical methodology we were unable to accurately measure amikacin below 
2ug/ml in equine plasma. This reason for the low recovery of amikacin in equine plasma by 
this method is unknown. The low amikacin recovery impacted on the variability of the data 
at lower concentrations and therefore, our reporting limits for this method were quite high 
compared with those for the saline method. The elution characteristics of amikacin were 
therefore not determined in equine plasma; hence our second hypothesis cannot be proved or 
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disproved. A previous study reported the elution characteristics of gentamicin from a 
calcium sulphate based delivery vehicle in porcine serum; revealing the elution 
characteristics were comparable to studies using phosphate buffered saline as the eluent.171  
The rate of elution of antimicrobials from calcium sulphate based implants is influenced by 
the crystal density, shape of the implant (surface area to volume ratio), amount of 
antimicrobial impregnated within the particular implant, and the volume and rate of 
refreshment of the wound fluid. The first three factors in this study were controlled by the 
manufacturer of the product, whereas the final factor was controlled by the study design. 
The method of sampling the eluent influences the rate at which antimicrobials elute from 
calcium sulphate based bio-implants; with complete refreshment of eluent leading to much 
more rapid of elution of antimicrobial, compared with the slower rates of elution that occur 
with only partial refreshment of the eluent at sampling times.198 As continuous agitation was 
not conducted throughout the study, we elected to completely refreshment the eluent in case 
the amikacin was not evenly distributed throughout the eluent, thereby not providing an 
accurate amikacin elution concentration. The complete refreshment of eluent should be taken 
into consideration when contemplating the use of this bio-implant clinically where the rate 
of refreshment of wound fluid may not be as high. The elution characteristics reported in this 
study may be more reflective of the amikacin elution characteristics from the implant in a 
highly exudative wound environment. 
Our third hypothesis that there would be no difference in the rate of degradation of the 
implant in phosphate buffered saline was not proven. The calcium sulphate hemihydrate-
dextran sulphate beads were consistently completely degraded in phosphate buffered saline 
by 72 hours, whereas they remained only partially degraded by 28 days in the equine 
plasma. It was noted that the beads developed a biofilm around them in the equine plasma, 
but the nature of the film was not determined in this study. Given amikacin is highly 
dissolvable in water and has less than 5% protein binding, the poor recovery of amikacin 
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from the bio-implant in equine plasma may have been due to the biofilm creating a barrier 
for diffusion of the amikacin out of the implant.199 However if the elution characteristics of 
amikacin from the bead were assumed to be similar to that in phosphate buffered saline then 
it brings in to question the propensity for this implant to promote antimicrobial resistance 
during the prolonged slow phase of elution of sub-therapeutic concentrations of 
antimicrobial. Furthermore, the persistence of the implant in equine plasma raises concerns 
regarding the implant acting as a foreign body or nidus for infection during the second slow 
phase of elution. 
Conclusion 
Amikacin eluted rapidly from the commercially available amikacin impregnated calcium 
sulphate hemihydrate– dextran sulphate beads in phosphate buffered saline. If this is a true 
reflection of elution in vivo then it calls to question the appropriateness of this bio-implant 
for in vivo use in the management of orthopaedic infections in the horse. Alternatively, the 
elution observed in phosphate buffered saline raises the question of the appropriateness of 
this model for assessment of in vivo elution of such implants. The slower dissolution of this 
bio implant in plasma compared to that in phosphate buffered saline also raises concerns 
about the potential for the implant to not only promote antimicrobial resistance due to 
prolonged low level antimicrobial elution, but also the propensity for the implant to act as a 
nidus for continued infection. 
Acknowledgments: 
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Calcium phosphate based biomaterials 
Bone consists of 70% inorganic mass (apatite) and 30% organic mass (collagen), with the 
predominant ions being that of calcium and phosphate.200 Bio-ceramics have a compatible 
composition of calcium and phosphate to bone and this has resulted in extensive study for 
their use as vehicles for local antimicrobial release and bone substitutes.200 Bio-ceramics are 
classified into three categories: Bioinert ceramics (Sintered alumina and zirconia), bioactive 
ceramics (bioactive glass) and bioresorbable ceramics (hydroxyapatite, sintered beta 
tricalcium phosphate).200 Bio-inert ceramics incite a low grade inflammatory reaction 
resulting in a thin fibrous tissue capsule that walls the implant off from the body where the 
implant persists. 
Hydroxyapatite 
Hydroxyapatite constitutes the inorganic part of bone and has imparted added benefits of 
local drug delivery in that it is biocompatible, bioactive encouraging new bone formation, 
and has high binding affinity for a variety of bioactive molecules.201 Hydroxyapatite is 
capable of releasing bioactive molecules for a prolonged period, along with aiding in space 
filling for reconstruction and regeneration of living tissue in the local area.201 A number of 
characteristics of fabrication of the hydroxyapatite have been shown to influence the 
effectiveness as a local drug delivery agent. The pore size of the hydroxyapatite has been 
shown to influence not only the elution of contained drugs but also the migration of 
osteoblasts and mesenchymal cells and matrix deposition in the empty space.202,203 The 
elution of antimicrobials from hydroxyapatite with lower pore percentage and majority 
micro pores has been found to be superior to constructs with higher pore percentage in vivo 
and in vitro; however it is thought that the ideal construct has a mixture of large pores to 
facilitate osteoblast ingrowth and small pores to sustain a release of antimicrobials at 
therapeutic concentrations over a protracted period of time.201 The pore interconnection of 
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hydroxyapatite also influences the performance as it imparts the channelling for cell 
distribution and migration, thereby allowing for efficient blood vessel formation.201 A bi-
model distribution of pore sizes has been proposed to be ideal; as large pore size encourages 
bone ingrowth whilst the small pores facilitate the slow prolonged release of the 
impregnated drug.204 A negative surface charge of hydroxyapatite scaffold has been shown 
to improve drug attachment, accelerate mineral deposition, reduce the time for cell 
attachment and improve the tissue ingrowth.201 The size of the antimicrobial molecules also 
has an influence on the rate of elution, as does the solubility of the antimicrobials.201  
The size, solubility and binding capacity of the antimicrobial to the biomaterial all influence 
the elution characteristics of the implant as a method for local antimicrobial delivery. The 
smaller the size of the antimicrobial molecule the faster the molecule can diffuse through the 
implant; the more soluble the antimicrobial the faster it will elute from the implant.201 The 
binding affinity of antimicrobials is determined by the number of available carboxyl groups, 
the more carboxyl groups the more intensely bound the molecule to the bio-ceramic and 
therefore the slower the release into the local tissue.205 A number of antimicrobials have 
been reported in research models to elute efficiently at therapeutic levels for a prolonged 
period, including gentamicin, fosfomycin, imipenem, amphotericin B and combined 
ceftriaxone sodium/sulbactam sodium.206,201  
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Chitosan: 
Chitin, a modified polysaccharide, is the structural component of arthropod exoskeletons, 
fungi cell walls, and cephalopod beaks, can be modified by removal of acetyl groups to form 
chitosan. Chitosan is a biodegradable and biocompatible polymer, which has various 
medical uses including artificial skin, absorbable suture material, wound healing 
accelerator.207 Immuno-enhancing, antitumor, antibacterial and hypocholesterol properties 
have also been identified and are thought to be dependent on the molecular size and 
chemical structure of the chitosan derivatives.207 Derivatives of chitosan have been 
chemically modified such that they differ in the arrangement and number of hydroxy and 
amino groups, which is thought to impart the physiological activity of the molecule.207 
Chitosan has been shown to reduce blood clot time in a dose dependant manner and increase 
the release of platelet derived growth factor AB and transforming growth factor B1.207 The 
mechanism of action by which chitosan and its derivatives cause haemostasis is thought to 
be independent of the classical path of coagulation, with no direct effects on the extrinsic or 
intrinsic pathways identified, rather it is thought to induce haemostasis enhancement of 
adhesion and aggregation of platelets.207,208 Much research has been directed towards 
combining chitin and chitosan with calcium based products such as calcium phosphate and 
hydroxyapatite to form composite materials that have the qualities of toughness and 
flexibility of the polymer, and strength and hardness of the calcium products, thus creating a 
bio-implant that would provide the scaffold for new bone growth (osteogenic potential) with 
the binder qualities of the polymer preventing implant migration and a suitable means of 
local drug delivery.209,210 These products have been studied as cements for bone defect filling 
and also engineered in-to microspheres for filling bone defects and local drug delivery.211-213  
In vitro studies have revealed release of gentamicin sulphate from pure chitosan scaffolds to 
have a similar bimodal elution pattern, as with PMMA and calcium sulphate, in that there is 
a high initial burst release of gentamicin followed by prolonged release at a lower level.214 
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The magnitude of release of gentamicin from the chitosan films is reported to be directly 
proportional to concentration of gentamicin incorporated into the film and to be inversely 
proportional to the level of cross linking of the chitosan.214 Composite materials have been 
shown to reduce the magnitude of the initial gentamicin release and maintain release at 
higher concentration for a more prolonged period  when compared to pure chiton films.210  
In vivo studies of the use of chitosan composites for local drug delivery have been 
promising. In a rabbit model of osteomyelitis treated with gentamicin impregnated chitosan 
bar it was found that approximately 11% of the total gentamicin was eluted in the first 24 
hours and then continued to elute and maintain local bone concentrations above MIC for 
over 8 weeks.215 A report of clinical use of gentamicin impregnated chitosan bars in the 
management of human chronic osteomyelitis has also yielded good results with gentamicin 
concentration in wound fluid several hundred times MIC for Staphylococcus aureus, 
achieving complete resolution of disease in 16 of 18 patients, and no systemic side effects, 
leading to the conclusion that gentamicin impregnated chitosan bars are a cheap, safe and 
effective local drug delivery device for treatment of chronic osteomyelitis.216 Research and 
clinical use of chitosan in the horse has so far not been documented, however holds much 
promise as a vehicle for local antimicrobial release. 
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Concluding comments: 
Management of orthopaedic infection in the horse has been vastly improved over the past 20 
years. This can be attributed to improved surgical and medical management of such 
conditions; and the institution of local antimicrobial therapy. Antimicrobial impregnated 
polymethylmethacrylate has not only contributed immensely to the improved success of 
management of orthopaedic infection in the horse, but has improved our understanding of 
pharmacokinetics and pharmacodynamics of local antimicrobial therapy. As not all 
properties of polymethylmethacrylate are ideal for impregnation with antimicrobials and for 
implantation into tissue for local antimicrobial release, alternate local delivery techniques 
have been developed. 
Clinically, intravenous antimicrobial regional limb perfusion and direct intra-synovial 
administration of antimicrobials has become common day practice in the management of 
orthopaedic infection in the horse. Previous reports of septic synovial structures have only 
instituted local antimicrobial therapy in selected cases and carried an association with non-
survival and reduced postoperative performance10, this however may have been biased due 
to only instituting local antimicrobial therapy in severe cases or those unresponsive to initial 
therapy. In the review of the use of local antimicrobial therapy for septic synovial structures 
at Murdoch University, all cases in the series underwent some form of local antimicrobial 
administration. The success of therapy in this case series is comparable to previous reports, 
and supports the use of local antimicrobial therapy in management of septic synovial 
structures in the horse.  
Bioresorbable implants have been less widely used in the horse and remain predominantly a 
research method of local antimicrobial administration. Calcium sulphate has been identified 
as a promising vehicle for local antimicrobial delivery; with positive attributes of bio-
absorption and osteoconductivity in the presence of osseous tissue but evokes no bone 
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formation in the absence of periosteum or bone. However an antimicrobial impregnated 
calcium sulphate implant that can provide therapeutic concentrations of antimicrobials for 
therapeutically relevant periods of time remains to be found. Closer examination of one 
commercially available amikacin impregnated calcium sulphate bead undertaken in this 
project revealed amikacin eluted rapidly from the beads in phosphate buffered saline. If this 
is a true reflection of elution in vivo then it calls to question the appropriateness of this bio-
implant for in vivo use in the management of orthopaedic infections in the horse due to the 
short period of antimicrobial elution. Alternatively, the elution observed in phosphate 
buffered saline raises the question of the appropriateness of this model for assessment of in 
vivo elution of such implants. The slower dissolution of this bio implant in plasma compared 
to that in phosphate buffered saline also raises concerns about the potential for the implant to 
not only promote antimicrobial resistance due to prolonged low level antimicrobial elution, 
but also the propensity for the implant to act as a nidus for continued infection. Many 
alternative calcium sulphate bio-implants have been studied, however to date none of these 
implants have been ideal. Research into alternate calcium sulphate composites, calcium 
phosphate bio-ceramics and chitosan compounds hold promise for development of the ideal 
implantable vehicle for local antimicrobial delivery. 
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